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Background: Endometriosis is a common gynaecological condition affecting at 
least 10% of women globally. It is a common cause for infertility in women and can 
be asymptomatic. This condition can also cause chronic pain and include 
symptoms such as dysuria, dysmenorrhea, fatigue, and nausea. Currently, 
invasive laparoscopy is the gold standard for diagnosis. Endometriosis occurs 
when endometrial stem cells (EnSCs) invade the body, implant and grow into 
ectopic lesions. These lesions can be found in many areas of the body including 
the peritoneal cavity, lungs, and the brain. There are currently four theories 
surrounding the process of endometriosis: retrograde menstruation, 
lymphovascular metastasis, embryonic rest, and coelomic metaplasia.  
Objectives: The main objective of this analysis was to discover a novel method 
to diagnose endometriosis at the earliest possible stage that could be used as a 
new gold standard procedure. 
Methods: Primarily, reviewing the growth, structure, and function of the 
endometrium was necessary to investigate how EnSCs can migrate to various 
areas of the body, attach, and grow into painful ectopic lesions. Following this, a 
PRISMA compliant random-effects meta-analysis was performed on 21 studies of 
peritoneal fluid (PF) of TNF-α, a cytokine that changes concentrations in the 
menstrual cycle, and could therefore possess potential differences in 
endometriosis patients as well. Finally, a study protocol was developed that could 
validate an early stage endometriosis diagnostics procedure for future 
implementation. 
Results: The meta-analysis of PF TNF-α yielded a significant difference (p<0.05). 
Although this study could not account for menstrual cycle stages, it has displayed 
support that protein concentration differences exist between endometriotic and 
non-endometriotic patients. Therefore, further analyses could be performed on 
different proteins in PF or serum to discover diagnostic candidates for 
endometriosis. This further supports the ideas described in the Study Protocol that 
possess the potential for implementation into diagnostic procedures. 
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Conclusions: There appear to be enough studies within the literature to perform 
similar PRISMA compliant random-effects meta-analyses of various 
endometriosis associated proteins. When these analyses are performed, the 
proteins with significant differences will be revealed and their potential explored 
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Chapter 1: Introduction 
1.1 Study Background 
Endometriosis is a gynaecological condition of ectopic lesion  growth in 
areas distant from the uterus (Yang & Huang, 2014). This disease affects 10-15% 
of women (Jerman & Hey-Cunningham, 2015) and can present symptoms of 
infertility, dysmenorrhea, and abdominal pain (Nap, Groothuis, Demir, Evers, & 
Dunselman, 2004), which can become chronic. In some instances, endometriosis 
can also be asymptomatic and cause infertility (Hickey, Ballard, & Farquhar, 2014). 
There are four prevailing theories regarding endometriosis: retrograde 
menstruation, lymphovascular metastasis, coelomic metaplasia, and embryonic 
rest (Figueira, Abrão, Krikun, & Taylor, 2011). Retrograde menstruation states that 
some EnSCs detach from the basalis during menstruation  (Lebovic, Mueller, & 
Taylor, 2011) and enter blood vessels throughout the body. These cells attach to 
a region distant from the uterus and develop into an ectopic lesion (Nap et al., 
2004). Lymphovascular metastasis is similar to retrograde menstruation except 
that the EnSCs migrate through the lymphatic system and produce a lesion distant 
from the uterus (Sasson & Taylor, 2008). Coelomic metaplasia occurs when 
tissues are modified into endometriotic lesions (Burney & Giudice, 2012); however, 
this theory is the least supported. Embryonic rest occurs when specific embryonic 
cells remain dormant; but will develop into endometriotic lesions that tend to be of 
a uterine tube origin (Santamaria, Massasa, & Taylor, 2012). However, with the 
multiple case studies present regarding each theory, the evidence suggests that 
there is no single cause of endometriosis. It appears that, depending on the 
circumstance, one of these theories is the cause for endometriosis in an individual, 
for example, a case study in a male regarding the embryonic rest theory 
(Gonzalez, Vnencak-Jones, Shi, & Fadare, 2014). In this instance the diagnosis 








As endometriosis is prevalent, it is worth discovering new methods for the earliest 
possible diagnosis. Presently, genome-wide associations are showing promising 
results that can predict or offer an alternative to some diagnostic practices (Nyholt 
et al., 2012; Painter et al., 2011). For example, one meta-analysis has shown that 
seven changes in single nucleotide polymorphisms (SNPs) have a strong genetic 
link associated with endometriosis that can be passed down to following 
generations (Nyholt et al., 2012). Alternatively, other analyses have shown that 
some genes such as Human Leukocyte Antigen (HLA), and Tumor Growth Factor 
beta Induced (TGFBI) are upregulated in endometriosis, while some genes 
associated with apoptosis such as Growth Arrest and DNA Damage 45A, 45B, and 
34 (GADD) were down-regulated (Arimoto et al., 2003). Further support of these 
findings was evident in endometriotic lesions where HLA-G is expressed; whereas 
it is not expressed in normal endometrium (Barrier, Kendall, Ryan, & Sharpe-
Timms, 2006). This may also explain some of the immune system evasion seen 
in endometriosis as when expressed HLA-G may reduce the sensitivity of 
endometriotic cells to NK and T-cell exposure (Barrier et al., 2006; Sundqvist et 
al., 2011).  
Currently, the gold standard is an invasive laparoscopy (Nezhat et al., 
2010). However, the issue with this is that a patient must be in pain and request 
for a diagnosis by a medical practitioner; or as in some asymptomatic cases 
(Hickey et al., 2014), will only be discovered upon patient request for an 
examination. Therefore, with this marked limitation, a different method of diagnosis 
is required to investigate if an early stage diagnostic procedure can be performed 
that is less invasive, cost effective, and allows for earlier patient treatment.  
 
1.2 Purpose of this study 
The purpose of this study is to evaluate if a new method for endometriosis 
diagnostics is plausible and less invasive than gold standard laparoscopy. To 
investigate the diagnostic plausibility; a review of the current literature is required 
regarding endometrial development and endometriosis. Th is can be used to 
discover if there are any specific protein concentration  changes that could be 
targeted as an endometriosis diagnostic measure. Furthermore, this review can 
address what is currently known about endometrial development and how 
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endometriosis uses this development procedure to cause ectopic lesion growth. 
This review can also evaluate what areas are well-known as well as the unclear 
biochemical mechanisms required for endometrial and endometriosis 
development. 
Subsequently, by investigating the mechanisms of endometriosis, a range 
of proteins can be targeted for diagnostics procedures. As endometriosis evades 
the immune system, various changes in multiple cytokines occur. Therefore, one 
of these proteins can be selected to further clarify its potential for endometriosis 
diagnostics. As diagnostic procedures can use a variety of sample types; two 
appear to be the most common for protein diagnostics: peritoneal fluid (PF) and 
serum. However, most cytokines in both sample types possess data set conflicts, 
therefore a meta-analysis will be performed to account for these conflicts and 
detect if a significant effect is present and consistent between studies. Following 
this, a study protocol is to be developed that can use this information to determine 
which proteins could be used from serum and PF for early-stage endometriosis 
diagnostics. 
 
1.3 Study Objectives 
For this meta-analysis, PF TNF-α was selected after searching the literature 
for proteins that commonly appeared in potential endometriosis diagnostic 
methods. In addition, no meta-analyses on PF TNF-α have been performed; 
furthermore, conflicts existed between the studies. Therefore, this random-effects 
meta-analysis has been performed to account for the conflicts between various 
studies. In addition, by using this same methodology, a study protocol has been 
proposed for further analysis of various proteins by using meta-analyses, 
reference range development, and a validation procedure to provide evidence for 
an early-stage endometriosis diagnostic procedure.  







1.4 Study hypotheses 
The main prediction of this study was that PF TNF-α possesses a significant 
difference between endometriotic and control patients when compared by meta-
analysis. The endometriotic patients were expected to have higher concentrations 
of PF TNF-α (pg/ml) compared to controls. PF TNF-α was expected to possess 
significance (p<0.05) at the heterogeneity level for performing a meta-analysis, as 
well as the final result when comparing multiple studies. It was also expected that 
by utilising meta-analyses, a procedure could be developed to diagnose 
endometriosis using PF and serum samples as a less invasive alternative to 
laparoscopy. 
1.5 Thesis layout 
For this thesis, the format for each chapter has been presented in the style of a 
manuscript prepared for journal publication. Chapter two is a literature review of 
endometrial development and the four current theories of endometriosis. Chapter 
three is a meta-analysis and study protocol. The first half of chapter three covers 
the PF TNF-α meta-analysis and its diagnostic potential. Subsequently, a study 
protocol is described in the second half of chapter three. This proposes using 
multiple meta-analyses of various proteins within PF and serum for use in a 
diagnostic procedure. Following this, a reference range and validation criteria has 
been defined that can clarify which protein candidates at specific menstrual cycle 
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Chapter 2: Literature review of endometrial development from hormonal 
and environmental stimuli, and the theories of endometriosis 
Abstract – Endometriosis is a painful chronic condition that commonly causes 
infertility in women. This review has been developed to analyse endometrial 
physiological development from environmental and hormonal stimuli as well as the 
current aetiology of endometriosis. Primarily endometriosis is most likely to be 
caused by the endometrial stem cells (EnSCs) detachment and dispersal through 
the body during the menstrual cycle (retrograde menstruation); followed by 
reattachment and growth at a new, non-uterine site, resulting in an endometrial 
lesion. In addition, EnSCs may travel through the lymphatic system 
(lymphovascular metastasis) and cause endometriosis in areas further away from 
the uterus. EnSCs are located in the endometrial basalis layer and proliferate by 
various hormones such as estrogen and progesterone in complex pathways 
discussed in this review in preparation for blastocyst reception. Therefore, by 
encompassing the physiological associations of EnSCs, the mechanisms of 
endometrial structure and development, and the current theories of endometriosis, 
this can allow for the potential of novel opportunities in medical laboratory 

















1. The Endometrium 
1.1. Structure 
 The endometrium is the inner lining of the uterus composed of two layers; 
the basalis and functionalis (figure 1.1) (Salamonsen & Lathbury, 2000). The 
functionalis region consists of the uppermost two thirds of the endometrium 
separated into two layers: stratum compactum (furthest from basalis) and stratum 
spongiosum (nearest the basalis) (Ayachit & Kulkarni, 2017) with a shallow folded 
layer of various glandular, luminal, and ciliated epithelial cells (Fay & Grudzinskas, 
1991; Kirk et al., 1978). The basalis is the lowermost third of the endometrium and 
involves the deeper interspersed crypts with endometrial stem cells (EnSCs). 
EnSCs are situated in the most basal region of these crypts to produce cells for 
the temporary functionalis layer (Ayachit & Kulkarni, 2017; Salamonsen & 
Lathbury, 2000). The basalis is attached to the subendometrial myometrium and 
remains attached after menstruation (Diedrich, Fauser, Devroey, & Griesinger, 
2007; Figueira, Abrão, Krikun, & Taylor, 2011). 
 
 
Figure 1.1: The basalis and functionalis regions of the endometrium as well as 
endometrial stem cells adapted from Gargett & Masuda (2010). eMSC: 
Endometrial mesenchymal stem cells. 
 
 Within basalis layer crypts, additional cell types exist that compose 
endometrial structure. These include: a dense stroma, large blood vessels, niche 
cells (Figueira et al., 2011), and a rich lymphatic network (Donoghue, Lederman, 
Susil, & Rogers, 2007). The dense stroma and large blood vessels provide a ready 
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supply of blood when the functionalis layer is constructed, and act as a stable 
foundation for growth, allowing endometrial regeneration after menstruation (Fay 
& Grudzinskas, 1991). The dense stroma provides a niche for the endometrial 
stem cells so that they are not lost during each menstrual cycle (Fayazi, Salehnia, 
& Ziaei, 2016). In regards to the lymphatic system, the growth and development 
of the basalis and functionalis layers are unclear; however, it does require vascular 
endothelial growth factors (VEGF) -C and -D, as well as VEGF receptor-3 (VEGF-
R3) and that these are more prevalent in the basalis than the functionalis 
(Donoghue et al., 2007). Niche cells immediately adjacent to EnSCs prevent EnSC 
differentiation and transmit paracrine signals to induce or reduce cell proliferation 
(Figueira et al., 2011); thus, acting similarly to the Paneth cells of the small 
intestinal stem cell regions (Clevers & Bevins, 2013). Depending on the menstrual 
cycle stage, EnSCs can be stimulated to replace removed or dead epithelial cells 
after bleeding to assist in endometrial recovery (Diedrich et al., 2007) which rapidly 
develops a new cellular barrier, presumably to prevent potential infection. 
Alternatively, as seen in later stages of the menstrual cycle, EnSCs can be 
stimulated to proliferate to form layers of stroma (Deligdisch, 2000) with a loosely 
attached outer epithelial layer in the functionalis in preparation for blastocyst 
implantation (Sharkey & Smith, 2003). 
 Furthermore, depending on the type of division, EnSCs can form various 
cell types. If the division is symmetrical, either two transit amplifying progenitors 
(TA) or two daughter stem cells are formed (Figueira et al., 2011). TA cells will 
repeatedly divide and accumulate various molecular markers for differentiation 
purposes (Figueira et al., 2011), while regular stem cells likely retain the same 
function as their parent cell. If the divisions are asymmetric, one daughter cell will 
be moderately differentiated and the other will be identical to the parent (Figueira 
et al., 2011). In addition, separate EnSCs become incorporated into the 
functionalis layer (Darzi, Werkmeister, Deane, & Gargett, 2016). These will be 
altered further into decidual cells in preparation for the blastocyst, or to generate 
and support other associated glandular tissue (Darzi et al., 2016).  
 The functionalis layer consists of proliferated cells lost in each menstrual 
cycle if a blastocyst has not implanted (Salamonsen & Lathbury, 2000). The 
majority of this layer is a loose connective stroma surrounding dense regions of 
glandular tissue (Figueira et al., 2011) with a multitude of blood vessels 
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(Deligdisch, 2000) as a supply of nutrients. This glandular tissue is a combination 
of epithelial, vascular, and stromal cells (Darzi et al., 2016).  
 Prior to implantation, the functionalis undergoes a rapid preparation 
process involving a glandular and supportive loose connective stromal layer 
(Gargett & Masuda, 2010). The primary layer of glandular tissue is likely to be 
composed of a pseudo-stratified columnar epithelium (Gargett & Masuda, 2010). 
The formation of glands and various cell types in the functionalis (adenogenesis) 
occurs in conjunction with proliferating stroma as a response to gradually 
increasing levels of 17-β estradiol from the growing follicle (Messinis, Messini, & 
Dafopoulos, 2014) alongside other hormones such as prolactin, insulin-like growth 
factor 1 and 2 (IGF-1, -2), fibroblast growth factor -7 and -10 (FGF-7, -10), and 
hepatocyte growth factor (HGF) (Gray et al., 2001). In addition, other factors such 
as cell proliferation involving site-specific variations, as well as endocrine, 
paracrine, and extracellular matrix (ECM) interactions cause specific responses 
on various cell receptors within the developing gland (Gray et al., 2001). Upon 
completion, these glands secrete a mucosal layer filled with various substances 
atop of pinopodes such as: integrins, calcitonin, and leukaemia inhibitory factor 
(LIF) in a receptivity window that permits blastocyst implantation (Sharkey & Smith, 
2003). Depending on the species this implantation window can be in the region of 
hours (e.g. rats: 24h) to days (humans, from day 5-10 after LH surge) (Sharkey & 
Smith, 2003). Outside of this window, the endometrium is no longer receptive of 
the blastocyst (Gray et al., 2001; Sharkey & Smith, 2003). 
 The growing stroma in the proliferative phase possesses a role in 
supporting blastocyst implantation (Sharkey & Smith, 2003). Upon implantation, 
these cells become highly secretory to facilitate growth and respond to 
progesterone to mediate further stromal cell growth and division (Sharkey & Smith, 
2003). The stroma also possesses fibroblastic cells (Deligdisch, 2000; Diedrich et 
al., 2007) that establish a collagen framework for their own cells, glandular cells, 
and blood vessels to grow into (Fay & Grudzinskas, 1991). The stromal cells may 
also function in endometrial metabolism; as well as the production of: prolactin, 
epidermal growth factor (EGF), and pregnancy-associated plasma protein (Fay & 
Grudzinskas, 1991). When stimulated by 17β-estradiol and progesterone, stromal 
cells secrete heparin binding epidermal growth factor (HB-EGF) to support 
successful implantation (Cavagna & Mantese, 2003; Sharkey & Smith, 2003). 
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These roles of the stroma cooperating with glandular cells and the basalis layer of 
the endometrium are critical for preparation of the arriving blastocyst and if they 
are not co-ordinated, the endometrium will not undergo pregnancy resulting in 
unsuccessful reproduction. 
 
1.2. Function  
 The primary function of the endometrium is to prepare for an arriving 
blastocyst and allow implantation so that the offspring can grow in-utero. In order 
to accomplish this, the endometrium must proliferate in regular cycles for the 
highest probability of successful reproduction. This process varies across species 
and is known as an estrous cycles or menstrual cycle depending on whether the 
endometrium is resorbed following unsuccessful blastocyst implantation  
(Baerwald, Adams, & Pierson, 2012; Driancourt, Gibson, & Cahill, 1985; Larson & 
Ball, 1992; Sato, Nasu, & Tsuchitani, 2016) For example, in humans, the 
menstrual cycle (endometrium discarded with unsuccessful implantation) occurs 
every 26-35 days (Baerwald et al., 2012); however, in some mammals such as 
sheep, these cycles are controlled by the number of daylight hours and will occur 
every 17 days but only in the late autumn-early winter periods (Evans, Duffy, 
Hynes, & Boland, 2000). This is termed photoperiodism where certain mammals 
have reproductive cycles based around the number of daylight hours. It allows the 
individual to produce offspring at a period where nutrients will be the most plentiful 
and allow the greatest chance for offspring survival.  
 
1.2.1. The Menstrual cycle 
 Menstrual cycles are induced by the hypothalamo-pituitary-gonadal (HPG) 
axis. Despite differences in time periods for the cycles, the pattern is relatively 
uniform across mammals with the exception of endometrial resorption (estrous 
cycle) or loss (menstrual cycle) at the end of the cycle (Sato et al., 2016). For 
humans, the primary cycle initiates at the onset of puberty, currently thought to be 
due to increasing kisspeptin levels (Liu & Herbison, 2016; Uenoyama et al., 2016) 
as well as elevated levels of glutamate, and decreased levels of γ-amino-butyric 
acid (GABA) in their respective neurons (Rojas et al., 2015). These changes in 
glutamate and GABAergic neuron activity are caused by naturally increasing levels 
of estrogen and progesterone (Messinis et al., 2014), which are thought to act on 
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their corresponding receptors of these two neuron types (Rojas et al., 2015) as the 
first cycle occurs. Interestingly, the mechanism for activation of estrogen and 
progesterone receptors in the glutamate and GABA neurons is unclear; however, 
the entire mechanism of puberty onset is being gradually revealed.  
 Gene expression of Kiss1 in kisspeptin neurons of the hypothalamus are 
one of the central controls for GnRH secretion (Uenoyama et al., 2016). The 
protein product; kisspeptin activates kisspeptin receptors in GnRH neurons to 
begin GnRH secretion and puberty onset (Liu & Herbison, 2016). Kiss1 is activated 
through epigenetic mechanisms regulated by estrogen (Uenoyama et al., 2016); 
however, the mechanism is unknown for the conversion from pubertal suppressor 
to activator. Current knowledge suggests it involves estrogen receptor-α (ER-α), 
as upon removal, it causes an immediate pubertal onset in mice; suggesting this 
receptor has an inhibitory function prior to puberty (Dubois, Wolfe, Radovick, 
Boehm, & Levine, 2016). One hypothesis suggests that ER-α has a bidirectional 
nature depending on the brain region in which it is located causing kisspeptin 
levels to increase or decrease; resulting in the primary GnRH surge for puberty 
onset (Uenoyama et al., 2016). Furthermore, depending on the brain region, 
kisspeptin either had an increase or decrease in expression around the time of 
puberty. For example, in the anteroventral periventricular nucleus (AVPV), 
kisspeptin levels increased while in the arcuate nucleus (ARC), levels decreased 
(Dubois et al., 2016; Uenoyama et al., 2016). Unfortunately, the exact mechanism 
for puberty onset is unclear prior to kisspeptin and ER-α expression and 
suppression. In addition, leptin also appears to act in a competitive manner as it 
also stimulates ER-α production in high fat diets, which suppresses puberty onset 
(Bless et al., 2016). Further investigation must be done in order to clarify the exact 
regulation of this mechanism. The current literature suggests that it involves a level 
of dietary requirement with leptin (Steinberg, Lowe Vandell, & Bornstein, 2009) 
activating a leptin - alpha-melanocyte stimulating hormone (α-MSH) pathway that 
stimulates kisspeptin (Manfredi-lozano et al., 2016; Watanobe, 2002).  
 The most probable pathway from leptin to kisspeptin is seen in figure 1.2 
below. Leptin as a result of dietary intake, digestion, and absorption will act on a 
leptin receptor of pro-opiomelanocortin (POMC) neurons in the hypothalamic ARC 
(Watanobe, 2002). This will activate a signalling pathway involving Janus Kinase 
(JAK) which will phosphorylate the leptin receptor and activate signal transducer 
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and activator of transcription 3 (STAT3) (Varela & Horvath, 2012). Upon 
phosphorylation, STAT3 binds to the POMC promoter to stimulate its production 
(Varela & Horvath, 2012). Simultaneously the phosphatidylinositol-3-kinase (PI3K) 
pathway is also activated and causes inositol triphosphate (IP3) to be developed 
from phosphatidylinositol 4,5-bisphosphate (PIP2) leading to 3-phosphoinositide-
dependent protein kinase 1 (PDK1) activation followed by Protein Kinase B (PKB) 
(Varela & Horvath, 2012). PKB will inhibit Forkhead box protein O1 (FoxO1) 
through phosphorylation, allowing further stimulation of POMC production as 
FoxO1 acts as a POMC inhibitor (Varela & Horvath, 2012). It should also be noted 
that insulin will act in the same manner as leptin on insulin receptors of the POMC 
neurons acting through the PI3K pathway (Varela & Horvath, 2012). Once POMC 
is made available, prohormone convertase 1 (PC1) will transform POMC into 
adrenocorticotropic hormone (ACTH) (Rousseau et al., 2008). Prohormone 
convertase 2 (PC2) will convert the ACTH into alpha-melanocyte stimulating 
hormone (α-MSH) with the assistance of acetylation and amidation (Rousseau et 
al., 2008). Following this, α-MSH will be secreted from the POMC neuron and 
received by melanocortin receptor 4 (MC4R) on Kisspeptin neurons in the preoptic 
area (POA) and the ARC (Manfredi-lozano et al., 2016). From this area of the 
pathway, the kisspeptin expression mechanism is not fully understood as in sheep 
α-MSH stimulates Kiss1 in the POA, yet decreases if bound to neurons in the ARC 
(Manfredi-lozano et al., 2016). In mice however, α-MSH in the ARC stimulates Kiss 
1 (Manfredi-lozano et al., 2016) further showing that puberty regulation has minor 
differences among species. 
 Once α-MSH is bound to the neurons promoting kisspeptin production, the 
exact signal transduction pathway used to create kisspeptin is also unclear. 
However, it appears most likely to be via the adenylate cyclase pathway as well 
as the phospholipase C pathway to activate kisspeptin (Haskell-Luevano & 
Hadley, 1999), however this is yet to be confirmed in the literature. A similar 
process exists upon stimulating GnRH, where these same pathways promote 
GnRH secretion in the GnRH neurons of the respective areas of the mammalian 
hypothalamus such as the POA and AVPV in rodents, and the POA and 
infundibular nucleus of humans (Marques, Skorupskaite, Rozario, Anderson, & 
George, 2015). In addition, kisspeptin causes more frequent and longer durations 
of depolarization of the GnRH neurons (Krsmanovic, Hu, Leung, Feng, & Catt, 
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2010). This implies that GnRH may be kept in vesicles, and similar to other 
neurotransmitters, may be transferred to the blood stream through this pathway. 
Furthermore, kisspeptin may also have a role in GnRH expression by acting 
through a Kiss Responsive Element that transfers histone deactylase 9 (HDAC9) 
from the cytoplasm to the nucleus where it alters how various transcription factors 







Figure 1.2: Potential pathway used to initiate GnRH production in the primary 
menstrual cycle based on current literature (Altarejos & Montminy, 2011; Haskell-
Luevano & Hadley, 1999; Messinis et al., 2014; Varela & Horvath, 2012). ARC: 
arcuate nucleus, Lep-R: Leptin receptor, p: phosphate, PI3K: phosphatidylinositol-
3-kinase, PDK1: 3-phosphoinositide-dependent protein kinase 1, POMC: 
proopiomelanocortin, stat-3: signal transducer and activator of transcription 3, Fox 
O1: Forkhead box protein O1, AKT: protein kinase B, PC1: Prohormone 
convertase 1, PC2: Prohormone convertase 2, ACTH: Adrenocorticotropic 
hormone, α-MSH: alpha-melanocyte stimulating hormone, MC4R: melanocortin 4 
receptor, G: G-protein, GTP: Guanosine triphosphate, AC2: adenylyl cyclase, 
ATP: Adenosine Triphosphate, cAMP: cyclic adenosine monophosphate, PKA: 
Protein Kinase A, CREB: cAMP response element binding protein, CRE: cAMP 
response element, Kiss 1 (inside nucleus): Kiss1 gene, Kiss 1 (outside nucleus): 
kisspeptin, kiss1R: Kiss1 receptor, POA: Preoptic area, KRE: Kiss response 
element, PIP2: phosphatidylinositol 4,5-bisphosphate, HDAC9: histone 
deacetylase 9, GnRHp: GnRH promoter, GnRH: Gonadotropin releasing 
hormone, PLC: Phospholipase C, IP3: inositol triphosphate, DAG: Diacylglycerol, 
PKC: Protein Kinase C, ER: endoplasmic reticulum, ME: Median eminence. 
 
 The brain regions containing glutamate and GABA neurons stimulate and 
inhibit neuron activity respectively. They exhibit roles in the onset of puberty 
independently of kisspeptin (Cheong, Czieselsky, Porteous, & Herbison, 2015) as 
well as promoting further follicle growth in the menstrual cycle. This is evident due 
to estrogen receptor -α (ER-α) expression on their neuronal surfaces (Cheong et 
al., 2015) that respond to low levels of estrogen prior to puberty, as well as the 
increasing levels during menstrual cycles. In the hypothalamus, glutamate 
neurons promote GnRH production (Clasadonte, Sharif, Baroncini, & Prevot, 
2011) and their neurons can be found in the ARC, paraventricular nucleus (PVN) 
and median eminence (ME) of the hypothalamus (Durand, Pampillo, Caruso, & 
Lasaga, 2008). GABA neurons, possess the function of inhibition and upon 
activation, inhibit other neurons from undergoing excitation. These neurons are 
also found in the ME (Durand et al., 2008) as well as various other brain regions 
to inhibit neuron activity. It is worth noting that other factors such as insulin and 
leptin have a role in GnRH secretion where leptin promotes FSH and LH 
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production (later resulting in greater GnRH production), while insulin promotes 
GnRH secretion and inhibits the GnRH suppressors GABA and neuropeptide-Y 
(NPY) (Rojas et al., 2015). It has been suggested that kisspeptin may have a role 
in glutamate activation and GABA inhibition, however this has not yet been 
confirmed (Liu & Herbison, 2016). In the glutamate neurons, ER-α is involved in 
the estradiol positive and negative feedback mechanism via different brain 
regions; however, in GABA neurons, ER-α is exclusively required for the positive 






Figure 1.3: GnRH secretion caused by estrogen acting through glutamate and 
GABA neurons and the effects of high pulse vs low pulses of GnRH (Boulware et 
al., 2005; Cheong et al., 2015; Moura & Petersen, 2010; Thompson & Kaiser, 
2014). E2: Estradiol, ER-α: Estradiol receptor-alpha, ARC: arcuate nucleus, POA: 
Preoptic area, PVN: Paraventricular nucleus, ME: Median eminence, mGluR1a: 
metabotropic glutamate receptor, G: G-protein, GTP: Guanosine triphosphate, 
PLC: Phospholipase C, IP3: inositol triphosphate, DAG: Diacylglycerol, PKC: 
Protein Kinase C, MAPK: Mitogen activated protein kinase, MEK: MAPK/ 
extracellular signal-regulated kinase (ERK), RSK: Ribosomal s6 kinase, CREB: 
cAMP response element binding protein, CRE: cAMP response element, GLUT: 
glutamate, Kiss 1 (inside nucleus): Kiss1 gene, Kiss 1 (outside nucleus): 
kisspeptin, kiss R: Kisspeptin receptor, GnRH: Gonadotropin releasing hormone, 
GABA: gamma amino butyric acid, LH: luteinizing hormone, FSH: Follicle 
stimulating hormone. 
 
 GnRH neurons possess a peculiar anomaly, they terminate at the ME 
(Campbell, Gaidamaka, Han, & Herbison, 2009). This is interesting because other 
neurons mentioned above also end at the ME suggesting that some 
neurotransmitters from the GABA and glutamate neurons may influence the GnRH 
neuron terminus in order to promote or inhibit GnRH secretion. However, it is more 
likely that glutamate and GABA also influence GnRH secretion from other brain 
regions, rather than the ME exclusively and directly. Furthermore, GnRH neurons 
are long and begin at various areas of the brain, including the nasal regions with 
cell bodies in multiple regions of the hypothalamus and medial septum (Campbell 
et al., 2009). GnRH neurons also aggregate together to allow the pulsatile 
releasing patterns observed to synchronize GnRH release (Campbell et al., 2009). 
When GnRH is released from the ME, it will travel through the hypophyseal portal 
blood system to the anterior pituitary. This activates the production of follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) (Figure 1.3) (Watanabe, 
Fukuda, & Nabekura, 2014).  
 When GnRH enters the anterior pituitary gland, it will bind to GnRH 
receptors found on gonadotrophs (Thompson & Kaiser, 2014). Gonadotrophs are 
cells that specifically secrete FSH and LH (Smith, Osianlis, & Vollenhoven, 2014). 
These gonadotrophs respond to the frequency of GnRH pulses to determine FSH 
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and LH secretion; where less frequent pulses promote greater FSH production and 
more frequent pulses promote both FSH and LH production (Thompson & Kaiser, 
2014). It is not entirely understood how this mechanism functions; however, the 
proposed mechanism is discussed in thorough detail in Thompson & Kaiser 
(2014). Currently it is known that GnRH pulse frequency promotes the common 
sub-unit that FSH and LH possess; common subunit-α (CGA) (Thompson & 
Kaiser, 2014). The difference between FSH and LH is the second subunit; FSH-β 
and LH-β; and these subunits are controlled by the different pulsing frequencies 
of GnRH (Thompson & Kaiser, 2014).  
 Upon secretion, FSH and LH will be transported to the ovary to stimulate 
follicle growth (Rama Raju et al., 2013). At this stage many primary follicles will be 
growing and become secondary follicles. These are characterized by having at 
least two layers of cuboidal granulosa cells with receptors for FSH to allow for 
further growth (Chaves et al., 2012; Dorrington & Armstrong, 2013; Rojas et al., 
2015). In response to FSH, secondary follicles will grow in size, secrete estradiol, 
and possess numerous granulosa cell layers (Baerwald et al., 2012; Rojas et al., 
2015). In addition, FSH will induce LH receptor expression in the secondary 
follicles and will cause each to become dependent on LH over FSH (Baerwald et 
al., 2012; Rojas et al., 2015). 
 At this stage, the follicle selection process commences. This selection is 
associated with unique differences between secondary follicles. The follicle that is 
selected contains the greatest amount of LH receptor expression, aromatase 
activity, and secretions of 17-β estradiol (Baerwald et al., 2012). In addition, bone 
morphogenetic protein-15 (BMF-15) and insulin-like growth factor binding protein 
(IGFBP) appear to have a role in follicle selection and maturation, but it is unclear 
how these mechanisms function (Gasperin et al., 2014; Mihm & Evans, 2008; 
Rossi et al., 2015). The maturing follicle that becomes the dominant follicle will 
possess an oocyte, multiple granulosa cell layers, and a fluid filled antrum. As the 
follicle matures and grows, it will produce more 17-β estradiol (Grachev & 
Goodman, 2016). This estradiol will promote further GnRH production in the 
hypothalamus and cause a surge in LH and FSH (Messinis et al., 2014; Mihm, 
Gangooly, & Muttukrishna, 2011; Rojas et al., 2015). The LH secreted allows the 
final follicle growth and maturation so ovulation (release of the ovum into the 
fallopian tubes) can occur (Grachev & Goodman, 2016). LH also stimulates the 
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granulosa cells to start releasing progesterone via a prostaglandin E2 pathway 
(Elvin, Yan, & Matzuk, 2000); and it is the combination of estrogen and 
progesterone that promote the greatest stages of endometrial lining growth. The 
menstrual cycle is summarized in figure 1.4 below. 
 
 












2. Mechanism of endometrial growth 
 
2.1. The role of estrogen 
 As the follicle matures and secretes greater levels of estradiol and 
progesterone, the endometrium responds by proliferation of the stroma, 
endometrial vascular glands, and blood vessels in the functionalis (Rogers, 
Lederman, & Taylor, 1998; Salamonsen, Kovacs, & Findlay, 1999). For 
proliferation to occur, estrogen will bind to receptors on the nuclear membrane 
(Hewitt, Winuthayanon, & Korach, 2016) of the basalis epithelial layer in the first 
menstrual cycle and in each subsequent cycle after menstruation (Gargett, Chan, 
& Schwab, 2008). Stromal layer proliferation is determined by the estrogen 
receptor dependent pathway (Thompson & Kaiser, 2014) (see figure 1.3 and 2.1) 
acting on transcription factor CCAAT enhancer binding protein beta (C/EBPβ) 
(Hewitt et al., 2016). Furthermore, ER-α and ER-β are also found in this epithelial 
layer (Gargett et al., 2008; Lecce, Meduri, Ancelin, Bergeron, & Perrot-Applanat, 
2001); however, these receptors are bound to chromatin sites prior to estrogen 
binding (Hewitt et al., 2016). Furthermore, progesterone may also have effects that 
inhibit estrogen receptor production (Koligan & Stormshak, 1977; Kurita et al., 
1998) and prevent estrogen mediated stromal proliferation (Robertshaw, Bian, & 
Das, 2016).  
 This stromal proliferation inhibition by progesterone is interesting as in the 
menstrual cycle, there appears to be no requirement for progesterone to inhibit 
estrogen receptor production. It is unclear in the literature why this inhibition 
occurs; however, an adjustment is observed as estrogen levels decline at this 
stage of ovulation, while progesterone levels increase considerably (see figure 
1.4) (Clayton, 2019). In addition, progesterone primes the endometrium for 
blastocyst reception at this stage and stimulates further stromal proliferation and 
glandular development (Robertshaw et al., 2016; Wetendorf & DeMayo, 2012). It 
is also important to note that the peak in progesterone levels indicate the transition 
from the proliferative phase into the secretory phase through preparing the 
endometrium for implantation by actions on the glandular functions within the 
functionalis (Slayden & Brenner, 2004). 
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 Once menstruation has completed along with the loss of the progesterone 
source (i.e. the corpus luteum (CL)) and any residual progesterone; the follicles 
and endometrial tissue will commence their growth with the initial increase in 
estrogen from maturing follicles (Messinis et al., 2014). When estrogen binds to 
ER-α or -β within the endometrial epithelial or stromal cell nuclei, it will promote 
the production of: EGF, IGF-1, and transforming growth factor-α (TGF-α) (Gargett 
et al., 2008). These factors are all required for the proliferation of stromal and 
epithelial cells (Gargett et al., 2008). In order for this to occur, estrogen may use 
one of four pathways to promote the production of these growth factors: a direct 
ligand dependent pathway, a tethered pathway, a non-genomic pathway, or by 
growth factor signalling (Heldring et al., 2007). The ligand dependent pathway 
involves estrogen binding to its receptor inside the cell and migrating to a 
transcription site where it immediately begins synthesis of one of the afore 
mentioned growth factors (Heldring et al., 2007). The tethered pathway is similar, 
except that the estrogen-estrogen receptor complex will bind to a transcription 
factor, then stimulate growth factor production (Heldring et al., 2007). The non-
genomic pathway involves the estrogen receptor using a second messenger to 
promote growth factor production (Heldring et al., 2007), and the growth factor 
signalling pathway involves a growth factor bound to a ligand acting on kinases to 
activate phosphorylated estrogen receptors to bind to the transcription site 





Figure 2.1: Various molecular pathways displaying how estrogen can stimulate 
other proteins to be produced for use in cellular proliferation (Heldring et al., 2007). 
ER: estrogen receptor, TF: transcription factor, SM: secondary messenger, NO: 
Nitric oxide, GF: Growth Factor, P: Phosphate molecule. 
 
 
 When estrogen causes greater expression of EGF, TGF-α and IGF-1, these 
will function in separate ways to promote mitosis. Specifically, these growth factors 
appear to have various functions in stromal and epithelial cells (Gargett et al., 
2008). EGF co-ordinates mitotic spindle development for chromosome splitting of 
daughter cells after the nuclear membrane has disappeared in the parent cell 
(Mardin et al., 2013). When applied it will accelerate the mitotic process through 
binding to epidermal growth factor receptor (EGFR) and activating a more rapid 
form of centrosome construction and separation to opposite poles of the cell 
(Mardin et al., 2013). TGF may also have a similar role as it can bind to the EGFR 
and stimulate the same process (Heldring et al., 2007). Furthermore, TGF appears 
to have a second potential role in causing apoptosis of decidualized cells by 
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phosphorylating the PI3-K/Akt protein kinase enzyme (Caron, Frechette-Frigon, 
Shooner, Leblanc, & Asselin, 2009).  
 IGFs act in an autocrine/paracrine positive feedback loop to increase 
mitosis of endometrial stromal and epithelial cells (Gray et al., 2001). To cause 
proliferation, IGF-1 using the MAPK pathway acts to increase ER-α production 
(Gray et al., 2001). As ER-α is produced and bound with estrogen from follicles, it 
increases the expression of IGF-1 and IGFR (Gray et al., 2001). As IGF-1 and 
IGFR are expressed, upon binding, the IGFs stimulate further production of ER-α 
using serine phosphorylation via the MAPK pathway, resulting in further mitosis 
promotion (Gray et al., 2001). Moreover, when expressed, IGF-1 also assists in 
angiogenesis as well as endometrial growth and proliferation (Cavagna & 
Mantese, 2003). This occurs through binding to IGF receptors on cell surface 
membranes and various binding proteins such as IGFBP-1, -2, or -3 (Fay & 
Grudzinskas, 1991). It is likely that the presence of various IGFs, the pathways 
they activate (An, Cheng, Yuan, & Li, 2010; Lathi et al., 2005; Spicer & Aad, 2007), 
their receptors, and binding proteins cause the differentiation seen in the 
functionalis layer. 
In addition, estrogen stimulates mitosis by increasing the expression of a 
cyclin-dependent kinase complex (CDK) (Groothuis, Dassen, Romano, & 
Punyadeera, 2007). CDK is an important part of the maturation promoting factor 
(MPF) protein complex (Casimiro, Crosariol, Loro, Li, & Pestell, 2012). This protein 
has many functions including: triggering the formation of a mitotic spindle, 
chromatin condensation, breakdown of the nuclear envelope, and fragmentation 
of the Golgi complex (Casimiro et al., 2012). Furthermore, estrogen also increases 
the expression of mitotic checkpoint component (MAD2) protein which interacts 
with the anaphase promoting complex used to promote the last mitosis stage 








2.2. The role of progesterone  
 While estrogen has the majority of its effects as a stromal and epithelial cell 
proliferator; progesterone has a role in stromal cell decidualization (Gargett et al., 
2008). Decidualization is the process of the endometrium responding to 
progesterone causing less stromal cell growth and division, greater differentiation 
of stromal and epithelial cells, as well as an increase in endometrial glandular 
secretions (Gargett et al., 2008; Sharkey & Smith, 2003). These secretions assist 
in blastocyst implantation (Gellersen & Brosens, 2014) and this process 
possesses species-specific differences. For example, in most mammals 
decidualization occurs as a response to blastocyst implantation (Sharkey & Smith, 
2003); however, in humans, this process occurs independently of implantation 
(Gellersen & Brosens, 2014; Wetendorf & DeMayo, 2012). 
 Progesterone is secreted near the time the mature follicle undergoes 
ovulation and continues for a time through the CL (refer to figure 1.4) (Clayton, 
2019; Messinis et al., 2014). Upon secretion, it will bind to either the 'A' or the 'B' 
isoform of the nuclear progesterone receptor (nPR) (Cheon et al., 2002; Wetendorf 
& DeMayo, 2012). The nPR is bound to chaperone proteins within the cytoplasm 
(Wetendorf & DeMayo, 2012). As progesterone is lipophilic, it will pass through the 
cell membrane to bind to the nPR (Gellersen & Brosens, 2014). Upon binding, it 
will enter the nucleus and act with co-regulators to cause gene transcription of 
specific targets such as Indian hedgehog for further decidualization, as well as 
cause chromatin alterations (Cheon et al., 2002; Wetendorf & DeMayo, 2012). 
Also, it can activate an MAPK pathway similar to estrogen, suggesting it may have 
a role in mitosis (Wetendorf & DeMayo, 2012). However, a paradox is present as, 
although it can stimulate the mitotic pathway, it will also inhibit it (Kim, Kurita, & 
Bulun, 2013; Wetendorf & DeMayo, 2012). This is through nPRs acting on the 
Hand2 transcription factor (Kim et al., 2013). When acted upon, Hand2 will prevent 
the expression of fibroblast growth factor ligands (Kim et al., 2013). These ligands 
are used in the process of expressing ER-α, and therefore, by preventing their 
expression, mitosis is inhibited as well (Wetendorf & DeMayo, 2012) as estrogen 
cannot activate the MAPK pathway of mitosis (Gray et al., 2001).  
 In order for endometrial stromal cell differentiation to occur, progesterone 
will act through an Indian hedgehog (Ihh) signalling pathway leading to activation 
of cytoplasmic foxO1 (Kim et al., 2013; Li et al., 2012; Wetendorf & DeMayo, 
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2012). The progesterone-progesterone receptor complex will act as a transcription 
factor to target the Ihh protein (Large & DeMayo, 2012; Wetendorf & DeMayo, 
2012). For the Ihh protein to be expressed, the gene must be transcribed and is 
only successfully produced when bound to the transmembrane receptor patched-
1 (PTCH-1) (Varjosalo & Taipale, 2008; Wetendorf & DeMayo, 2012). This PTCH-
1 will allow a transmembrane receptor smoothened (SMO) to activate, resulting in 
a downstream activation of the chicken ovalbumin upstream transcription factor-II 
(COUP-TFII) (Large & DeMayo, 2012; Wetendorf & DeMayo, 2012) (the Ihh 
protein after binding with progesterone-progesterone receptor complex will also 
promote COUP-TFII activity in a similar manner (Wetendorf & DeMayo, 2012)). 
COUP-TFII will consequently bind to bone morphogenetic protein 2 (BMP2) (Large 
& DeMayo, 2012; Li et al., 2012) to act on the wingless-related murine mammary 
tumour virus integration site 4 (WNT4) ligand (Large & DeMayo, 2012). This uses 
a β-catenin signalling pathway (Li et al., 2012) to act on the FOXO1 transcription 
factor (Large & DeMayo, 2012). This transcription factor will be used to promote 
genes such as: somatostatin (SST), decorin (DCN), left-right determination factor 
2 (LEFTY2), and b-cell lymphoma 2-like 11 (BCL2L11) that allow for differentiation 
of endometrial stroma (Li et al., 2012). This process has been summarized in 
figures 2.2 and 2.3 below. 
  Interestingly, progesterone will only assist endometrial gland development 
if secreted at the correct time within the menstrual cycle (Wetendorf & DeMayo, 
2012). If secretion occurs outside this window, it can be detrimental to the stage 
of preventing gland formation (Wetendorf & DeMayo, 2012). The main function of 
progesterone in gland development is leukaemia inhibitory factor (LIF) production 
(Wetendorf & DeMayo, 2012). LIF is used as a binding site for the implanting 
blastocyst and is produced in the expanding endometrial epithelium (Jeong et al., 
2010). For LIF production, it is likely to be secreted using a similar pathway seen 
in figures 2.2 and 2.3 via FOXA2 (Jeong et al., 2010). This would occur through 
use of a similar transcription factor and activation (Jeong et al., 2010) to that of the 









Figure 2.2: Complete pathway in endometrial stroma showing the effects of 
progesterone receptors on various signalling pathways adapted from Large & 
DeMayo, (2012). Solid arrows indicate induction, dashed arrows indicate potential 
pathways but with lacking evidence, barred solid lines indicate inhibition (Large & 
DeMayo, 2012). PR: progesterone receptor, Ihh: Indian hedgehog protein, pER-α: 
epithelial estrogen receptor α, pErk: eukaryotic translation initiation factor 2-alpha 
kinase 3, Fgfr: fibroblastic growth protein receptor, COUP-TFII: chicken ovalbumin 
upstream promoter-transcription factor 2, EGFR: epidermal growth factor receptor, 
Bmp2: bone morphogenetic protein 2, Hand2: Heart and neural crest derivatives-
expressed protein 2, Fgf: fibroblastic growth factor, Cox2: cyclo-oxygenase-2, 
Wnt4: wingless-related murine mammary tumour virus integration site 4, HB-EGF: 
heparin binding-epidermal growth factor, Hoxa10: homeobox A10, Fkbp: FK506 






Figure 2.3: One of the pathways used by the nPR to activate FOXO1 to induce 
differentiation of endometrial stem cells in humans, adapted from Li et al., (2012). 
Abbreviations: cAMP: cyclic adenosine monophosphate, PR: Progesterone 
receptor, BMP2: bone morphogenetic protein 2, WNT4: wingless-related murine 
mammary tumour virus integration site 4, FOXO1: forkhead box protein O1, SST: 
somatostatin, DCN: decorin, LEFTY2: left-right determination factor 2, BCL2L11: 















 3.1. Definition, and hypotheses 
 Endometriosis is the presence of functional endometrial stroma and glands 
outside of the uterine cavity (Nap, Groothuis, Demir, Evers, & Dunselman, 2004). 
It is a common chronic condition involving an endometrial tissue implant into 
various regions of the body, causing mild to severe pain (Yang & Huang, 2014). 
These implants are usually found in the fallopian tubes, uterus, ovaries, lungs, 
peritoneum, and renal tract (Bendon & Becker, 2012; Yang & Huang, 2014). 
Endometriosis is believed to be the cause of reproductive failure in women and 
can result in crippling psychological suffering and anxiety (Bendon & Becker, 2012; 
Yang & Huang, 2014). The cause of endometriosis is unclear; however, several 
theories have arisen such as: Retrograde menstruation, coelomic metaplasia, 
embryonic rest, and lymphovascular metastasis (Figueira et al., 2011). It is also 
plausible that endometriosis has multiple causes instead of a singular cause, 
however this is also unconfirmed (Sasson & Taylor, 2008). It should also be noted 
that the uterus is also an ‘immunologically privileged site’ (Jerzak & Bischof, 2002). 
This means an inflammatory response such as T-cell or Natural Killer cell 
responses do not occur while a lesion is present in the uterus (Jerzak & Bischof, 
2002). This is likely due to the gene expression of HLA-G, which is known to 
prevent the NK and T-cells from destroying endometriotic lesions (Barrier et al., 
2006; Sundqvist et al., 2011). The result of this makes the uterus vulnerable to 
diseases or conditions such as endometriosis or other infections in this area. 
 
3.1.1. Retrograde menstruation 
  This is also known as the Sampson theory (Lebovic, Mueller, & Taylor, 
2011) and describes shed cells from the menstrual cycle adhering to a non -uterine 
surface, causing an ectopic growth (Nap et al., 2004). This can occur through the 
spillage of viable endometrial cells from the peritoneum (Lebovic et al., 2011) 
entering the blood vessels. Initially when endometrial cells (resistant to apoptosis 
and phagocytosis) bind to the walls of any area to cause growth outside of the 
uterus (Lebovic et al., 2011); some of the immune system may not be activated as 
the cells are still considered to be 'self' and therefore an immune response is not 
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performed. This cellular adhering occurs through Intercellular adhesion molecule-
1 (ICAM-1), focal adhesion kinase (FAK), and matrix metalloproteinases (MMP) 
(Kyama, Debrock, Mwenda, & D'Hooghe, 2003).  
 ICAM-1 is a cell adhesion molecule usually involved in leukocyte trans-
endothelial migration, allowing endothelial binding prior to transmigration through 
the endothelial basement membrane into various tissues (Lawson & Wolf, 2009). 
However, when endometrial cells secrete and utilize ICAM-1, there are two effects: 
competition for space with leukocytes, and immunosurveillance evasion (Lebovic 
et al., 2011). This unique combination allows endometrial stem cells to grow into 
functional stroma and glands on non-uterine surfaces without immune system 
interference. Furthermore, interleukin-6 (IL-6) secreted by endometriotic cells may 
also play a role through the γ-interferon pathway to produce greater levels of 
soluble ICAM-1; resulting in further adhesion of other endometriotic cells (Kyama 
et al., 2003). In Sampson (1927), endometrial tissue fragments were discovered 
in uterine veins after menstruation suggesting that endometriosis could occur in 
any region of the body if the cells travel through the blood stream (Sampson, 
1927). This observation was further supported by the detection of endometrial cells 
circulating in the blood stream (Chen et al., 2017). These observations greatly 
validate the idea of retrograde menstruation as this can explain the locations of 
endometriotic lesions in the various regions of the body described above (Bendon 
& Becker, 2012; Yang & Huang, 2014). 
 Focal adhesion kinase (FAK) is found in most cells of the body and is an 
important part of cell-cell adhesion (Flamini, Sanchez, Genazzani, & Simoncini, 
2011; Mu et al., 2008). However, in endometriosis, this enzyme is expressed at 
greater levels in endometriotic tissue specifically, thus indicating its potential role 
(Mu et al., 2008). FAK acts as a signalling protein and is located on cell attachment 
sites that bind to the cytoskeleton using integrin receptors (Mu et al., 2008). In 
order to function, this tyrosine kinase enzyme must be phosphorylated to allow cell 
adhesion to occur (Flamini et al., 2011). When estrogen binds to ER-α or -β, it can 
cause this phosphorylation (Flamini et al., 2011). Therefore, if the cells survive 
through the use of ICAM-1 to avoid immunosurveillance (Lebovic et al., 2011), 
estrogen will be able to activate FAK to allow further binding and attachment 
(Flamini et al., 2011) as well as proliferation and growth of endometrial stroma and 
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glands (Rogers et al., 1998; Salamonsen et al., 1999) outside of the uterus 
resulting in endometriosis. 
 FAK and ICAM-1 act malevolently outside of the uterus through allowing 
painful ectopic endometrial growths as a result of being able to bind to the ECM 
as well as avoid and compete for space with the immune system. However; MMPs 
also possess an endometriotic role (Kyama et al., 2003). MMPs are zinc-
containing, Ca2+-dependent endopeptidases involved in cell adhesion (Verma & 
Hansch, 2007). These proteins break down collagen and the ECM (Nap et al., 
2004) permitting an invasion site for endometrial cell binding. MMPs are usually 
expressed at their highest levels in the late secretory phase of the menstrual cycle. 
Due to this property, it can also lead to endometrial cells being able to implant into 
ex-utero areas (Nap et al., 2004). Also, MMPs are upregulated in the presence of 
tumour necrosis factor (TNF-α) and interleukin-1 (IL-1) (Kyama et al., 2003), which 
also increase in concentration at the secretory phase, and during the early and 
late luteal phase respectively (Philippeaux & Piguet, 1993; Simon et al., 1993), 
which may promote endometriotic growths. TNF-α also inhibits the tissue inhibiting 
metalloproteinases (TIMP), required to inhibit MMP overexpression (Amălinei, 
Căruntu, Giuşcă, & Bălan, 2010). When TIMP is inhibited, MMPs can effortlessly 
cause greater ECM degradation and increase the number of sites for potential 
endometrial cells to implant and cause endometriosis. 
 FAK, ICAM-1 and MMPs are the major proteins involved in endometriotic 
implantations. These three factors also present support for the retrograde 
implantation theory as one method of how endometriosis can occur. By escaping 
through broken blood vessels in each menstrual cycle, it would not be difficult for 
a portion of the endometrial cells to enter the bloodstream and implant in other 
locations using ICAM-1, FAK, and MMPs. In addition, as ICAM-1 acts as a protein 
to assist in membrane binding as well as its immunological evasion properties; 
along with the adhesive nature of FAK; and the lysis of the ECM by the MMPs, 
invasion of endometrial cells would be very difficult to prevent. Furthermore, as the 
endometriotic cells respond to the same hormones as EnSCs in the menstrual 
cycle for growth, lesions of endometrial tissue appear to be very difficult to prevent 
once invasion into the bloodstream from a menstrual cycle has occurred. 
Furthermore, this theory has validity from more cases of endometriosis occurring 
on the intestinal left side than the right (Al-Fozan & Tulandi, 2003). This is due to 
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the left side colon being closer to the fallopian tube when compared to the right, 
resulting in a higher probability of cellular adherence from endometrial cells upon 
shedding in menstrual cycles (Story & Kennedy, 2005). 
 
3.1.2. Coelomic metaplasia 
This theory involves peritoneal tissue modification into ectopic endometrial tissue 
(Burney & Giudice, 2012). It is believed that hormonal or immunological influences 
can cause this alteration (Sourial, Tempest, & Hapangama, 2014); however, such 
growth factors have not been identified. This theory is not as well supported in the 
literature compared to retrograde menstruation. In addition, few reports exist on 
how this mechanism operates. It is believed that this form may play a role in deep 
endometriosis observed in pre-pubescent (Sourial et al., 2014), and adolescent 
girls (Brosens, Gordts, & Benagiano, 2013). Evidence for this comes from a study 
on female rabbits where metaplasia was induced (Vinatier, Orazi, Cosson, & 
Dufour, 2001). Also, an in-vitro study suggests that endometrial stromal and 
surface epithelia with a 10-fold increase of 17-β-estradiol cause metaplasia of the 
adjacent mesothelial cells to become ectopic endometrial cells (Vinatier et al., 
2001). Moreover, evidence from case studies of patients with Mayer-Rokitansky-
Kϋster-Hauser syndrome presents evidence from individuals with no functioning 
uterus, yet endometriosis has still occurred (Mok-Lin, Wolfberg, Hollinquist, & 
Laufer, 2010; Troncon et al., 2014) giving more plausibility to this theory.  
 
3.1.3. Embryonic rest 
 Embryonic cell rest involves a dormant state of embryonic cells with a 
probable Müllerian (uterine tube) origin (Santamaria, Massasa, & Taylor, 2012). 
The theory proposes these cells exist in the peritoneal cavity or elsewhere that 
can be induced into endometriotic tissue (Figueira et al., 2011). Alternatively, this 
type of endometriosis could be the result of an embryogenesis defect by some 
embryonic cells persisting and developing into endometriotic lesions upon 
estrogen exposure (Sourial et al., 2014). There is little evidence for this theory 
(Sasson & Taylor, 2008); however, verification of this theory exists where males 
exhibit endometriosis (Gonzalez, Vnencak-Jones, Shi, & Fadare, 2014). This 
occurs through initial growth stages by the development of female-specific 
33 
 
structures usually inhibited in the presence of the male genome (Sasson & Taylor, 
2008). Therefore, for this type of endometriosis to occur, a currently unknown 
method must exist where cells remain uninhibited until estrogen exposure occurs. 
This form of male endometriosis is rare and exists only in case reports (Gonzalez 
et al., 2014). Cases of male endometriosis are linked to estrogen therapy for 
prostate cancer (Gonzalez et al., 2014); further suggesting the plausibility of the 
embryonic rest or coelomic metaplasia theory for endometriosis onset in males. 
After exposure to estrogen, the now active cells will likely use ICAM-1, FAK, and 
MMPs to bind and allow growth of such endometriotic lesions. 
 
 
3.1.4. Lymphovascular metastasis 
 This theory states that endometrial cells enter through the lymphatic system 
and as a result, will cause endometriosis in regions further away from the uterus, 
reaching as distant as the brain (Sasson & Taylor, 2008). It was thought that if 
endometrial cells could enter the blood stream and cause endometriosis, therefore 
it could do something similar using the lymphatic system (Sampson, 1927). Within 
the endometrial basalis layer, there are large and great numbers of lymph nodes 
(Jerman & Hey-Cunningham, 2015; Red-Horse, 2008). These draining lymph 
nodes allow effortless access for endometrial cells to invade far-reaching areas of 
the body in the menstrual cycle (Jerman & Hey-Cunningham, 2015). In addition, 
as described above, the endometrial cells evade white blood cell detection 
(Lebovic et al., 2011), and pass through tight endothelial layers (Lawson & Wolf, 
2009) thus permitting them to travel great distances, implant, and grow into painful 










Endometriosis is the result of EnSCs escaping the uterus, adhering to 
various body regions, and causing painful lesion growths. Due to the prevalence 
of this condition; a review and analysis of endometrial development, the menstrual 
cycle with its underlying molecular mechanisms, and the resulting potential causes 
of endometriosis was performed. As the endometrium develops, it will go through 
regular cycles where the basalis will develop the temporary functionalis layer from 
EnSCs located in the basalis crypts. The first cycle is likely initiated from kisspeptin 
stimulation resulting from leptin production caused by natural dietary intake. 
Kisspeptin acts to cause the early surge of GnRH in pulsatile stages to act on the 
anterior pituitary gland where LH and FSH are developed and transported to the 
ovary for follicular development. As follicles mature, a single follicle is selected by 
various molecular mechanisms and causes further stimulation to allow endometrial 
functionalis growth in preparation for blastocyst arrival. However, should there be 
no blastocyst reception, menstrual bleeding will occur and the functionalis layer is 
discarded. As a result, EnSCs are occasionally lost through menstrual bleeding, 
enter the body, and use ICAM-1, MMPs, and FAK adhering molecules to permit 
endometriotic lesion growth in various body regions once an attachment site is 
formed. The EnSCs escape through the blood stream (retrograde menstruation) 
or the lymphatic system (lymphovascular metastasis) to generate endometriotic 
lesions. Alternatively, embryonic rest and coelomic metaplasia may occur where 
stem cells are induced to become endometriotic lesions throughout the body. The 
resulting endometriosis is chronic and painful where lesions develop in abnormal 
locations while avoiding immune system detection. Therefore, by understanding 
endometrial growth mechanisms, the menstrual cycle, and endometriosis 
development; novel diagnostic methods and medical procedures can be 
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Chapter 3a: Tumour necrosis factor-alpha meta-analysis: Early 
endometriosis diagnostics 
 
Abstract - Endometriosis causes symptoms of pelvic pain, discomfort, fatigue, 
nausea, and infertility. Diagnostic methods include invasive laparoscopies, testing 
serum, peritoneal fluid (PF), or peritoneal lavages (PL). Tumour necrosis factor-
alpha (TNF-α) is a potential endometriosis diagnostic candidate which 
differentiates between endometriotic and non-endometriotic patients. However, 
contradictions exist between studies; therefore, this PRISMA compliant meta-
analysis was performed to evaluate the potential of TNF-α for an early stage 
diagnostic procedure. PF studies were identified to compare TNF-α levels (pg/ml) 
between fertile controls against endometriosis patients. Where means and 
standard deviations were not available, estimation methods1, 2 were implemented. 
Our inclusion criteria identified 19 studies with 1075 patients. A Standard Mean 
Difference (SMD) random model compared PF TNF-α differences. Statistical 
significance (p<0.05), with an SMD of 2.1753 (Confidence Intervals: 0.2598 and 
4.0908) suggests that TNF-α can be used as an early endometriosis indicator. 
Analysis limitations included: no TNF-α gold standard, studies not including 
menstrual stage at time of PF extraction, and incomplete data sets. As TNF-α is a 
general inflammatory cytokine; for diagnostic procedures, other cytokines and 
growth factors such as transforming growth factor-β (TGF-β), and Interleukins-1 
and -10 (IL-1 and -10) should also be included from specific menstrual cycle 
stages. For diagnostic testing, a biochemical analyser or multiplex immunoassay 
using PF samples for early stage endometriosis is proposed as both tests can 
assay multiple factors in one procedure. 
 






Abbreviations: rAFS: revised American Fertility Society, TNF-α: tumour necrosis 
factor-alpha, PF: Peritoneal fluid, PL: Peritoneal lavage, ICAM-1: Intercellular 
adhesion molecule-1, FAK: focal adhesion kinase, NF-ĸB: Natural Factor-Kappa 
B, PP14: Placental protein 14, IL-1: Interleukin-1, IL-10: Interleukin-10, MEKK’s: 
mitogen activating protein kinase kinases, CSF: cerebrospinal fluid, IRMA: 
immunoradiometric assay, ELISA: enzyme-linked immunosorbent assay, VEGF: 




Endometriosis is a painful condition causing infertility and affecting the quality of 
life in women3 and is problematic to diagnose non-invasively in early stages. It 
involves the presence of lesions from endometrial stroma and glands outside of 
the uterus4. These lesions can be present in many areas of the body including the 
pelvic cavity, lungs, and the brain5. There are four theories surrounding the cause 
of endometriosis: retrograde menstruation, embryonic rest, lymphovascular 
metastasis, and coelomic metaplasia6. Usually diagnosis of endometriosis 
involves invasive laparoscopy to confirm the afflicting condition by visual 
inspection for endometrial lesions in abnormal locations7. Furthermore, the timing 
of diagnosis is also difficult as it is generally diagnosed after a patient has reported 
symptoms aligned with endometriosis, or, as in some infertility asymptomatic 
cases, an evaluation is performed for endometriosis8. Therefore, with such 
treatments being required, it is highly desirable to develop a simple, less invasive 
diagnostic test to confirm endometriosis in women 9, 10. To investigate if such tests 
can be implemented, this meta-analysis has been performed for the potential of 
TNF-α as a candidate as one of the diagnostic factors for developing a less or non-
invasive endometriosis test. 
 
TNF-α, a 27kDa cytokine in its uncleaved form is one of the pro-inflammatory 
cytokines involved in endometriosis11, 12 and was originally identified in studies of 
haemorrhagic tumour necrosis13. It is part of the primary non-selective (innate 
immune) defence mechanism against infection and is one of the factors involved 
in tumour destruction within the body13, 14 as well as roles in cell survival, and 
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inflammation15. This cytokine can be found in and is secreted from various white 
blood cell types including activated macrophages, B-cells, T-cells, and 
neutrophils16. These blood cells are associated with the endometriotic lesion and 
produce TNF-α. In addition, TNF-α is also produced in response to other diseases, 
for example: Mycobacterium tuberculosis17, and bacterial meningitis from CSF 
(cerebrospinal fluid)18, displaying how common elevated levels are in a variety of 
conditions or disease states.  
  
The appearance of TNF-α in the formation of endometriosis is clear in the 
retrograde menstruation theory where endometrial tissue enters the peritoneal 
cavity from fallopian tubes6 and begins with an adhesion stage. Adhesion occurs 
through Intercellular adhesion molecule-1 (ICAM-1), metalloproteinases (MMP), 
and focal adhesion kinase (FAK)19. Furthermore, to promote the growth of 
adhesions, the immune response is either not activated and becomes resistant to 
apoptosis9, or tumour formation is enhanced by TNF-α activating signal 
transduction pathways to produce Natural factor–kappa B (NF-ĸB)12. TNF-α is 
regulated by Placental Protein 14 (PP14), Interleukin -1 (IL-1), and progesterone20, 
and these three may unintentionally promote TNF-α in this instance. When TNF-α 
is produced it will bind to TNF receptors 1 and 2, activating the MEKKs (mitogen 
activating protein kinase kinases)12. When this occurs, a series of downstream 
phosphorylation reactions occur with resulting increases in NF-ĸB12. When 
activated in this manner, apoptosis is suppressed, allowing enhanced 
tumorigenesis12. 
 
Currently PF TNF-α is not used for diagnostic procedures due to conflicting results 
between studies. Therefore, this meta-analysis has been performed with the 
objective to investigate if and how this cytokine can be utilised as one of the early 
diagnostic factors for endometriosis although such variations of statistical and non-
statistical significance exist9, 15. Studies possessing PF or PL TNF-α in pg/mL were 
obtained through various databases for patients with and without confirmed 
diagnosis of endometriosis. Where possible, studies with data for revised 
American Fertility Society (rAFS) stages I-II early endometriosis stages21 were 
used in preference for this analysis. Interventions for all studies analysed were 
approved by the relevant human ethics boards for the associated research and 
45 
 
involved laparoscopies to confirm endometriosis prior to obtaining PF TNF-α 
samples. Various diagnostic assays were performed and all were included in this 
meta-analysis; for example, the ELISA (enzyme immunosorbent assay), bioassay, 
IRMA (immunoradiometric assay), multiplex immunoassay, the ImmuliteTM 
biochemical analyser, and Cytometric bead array. All diagnostic medical 
laboratory procedures were included as no official gold standard has been 
developed for TNF-α. Although few studies indicate that the ELISA is the gold 
standard22; it is important to note that there is no reference as to the reasoning or 
validation procedures involved to support the ELISA to be the most accurate test. 
The outcome of this analysis possessed statistical significance (p<0.05), however, 
an imprecise, large effect was also present. This effect possibly comprised of a 
number of variables not accounted for with  PF samples further explained in the 
discussion. However, the large effect was reflected in the raw data as evidenced 
by the range of values in TNF-α levels. Consequently, once a number of conditions 
are met as described in the discussion, this cytokine should be re-evaluated by a 
secondary meta-analysis to confirm any conflicts between previous studies of its 




2.1 Searches and study criteria 
 
The databases used for this analysis included: NCBI (PubMed), Scopus, 
ResearchGate, Ovid, EBSCO Business Source Premier, Web of Science, and 
Google Scholar using the following terms: “meta-analysis, endometriosis, 
macrophages”, “TNF-α”, “tumour necrosis factor-α”, “endometriosis”, “PF”, and 
“peritoneal fluid” with many terms used simultaneously. From these search 
engines, studies were identified and screened for potential use in this analysis. 
Furthermore, references from the included studies were also identified for analysis 
as well. Some studies were obtained from Science Direct by use of the reference 
screened papers. Where research papers were not available, authors were 
contacted through ResearchGate. The meta-analysis criteria involved any study 
measuring TNF-α (pg/ml) in PF or PL and comparing these levels between normal 
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and endometriotic patients. Comparisons of other infertility associated diseases to 
standard endometriosis were not included. For this meta-analysis, ethical approval 
was not required as all studies were based on published articles. Furthermore, a 
risk of bias according to Higgins et al23 was performed on all studies (Table 1). 
 
2.2. Data extraction and synthesis 
 
All data were collected and collated in Microsoft Excel. Selected studies 
had raw data values for TNF-α in pg/ml with conversions performed as necessary. 
From these, sample sizes, means, and standard deviations were used for the 
analysis. Sample sizes were provided in all studies, however, where means and 
standard deviations were not provided, statistical estimation formu las from Hozo 



































































































































































































(Kalu et al., 2007) High Low Low Low Low High 
(Podgaec et al., 2007) High High Low Low Unclear Low 
(Cheong et al., 2002) High Low Low Low Low Low 
(Harada et al., 1997) High High Low Low High High 
Bedaiwy et al., 2002) High Low Low Low Low Low 
(Richter, Dorn, Rosing, 
Flaskamp, & Ulrich, 2005) 






High High Low Low Low Low 
(Dziunycz et al., 2009) High High Low Low Low Low 
(Barcz et al., 2012) High Unclear Low Low Low Low 
(Drosdzol-Cop & 
Skrzypulec-Plinta, 2012) 
High Low Low Low Low Low 
(Wickiewicz et al., 2013) Low Low Low High Low Unclear 
(Pizzo et al., 2002) High Low High Low Low Unclear 
(Rana et al. 1996) Low Low Low High Low Low 
(Salmeri et al., 2015) Low Low High High Low Low 
(Skrzypczak 1995) Low Low Unclear Low Low Unclear 
(Wang et al. 2018) High High High High Unclear Unclear 
(Liu et al. 2000) Low High High Low Low Unclear 
(Oepomo, T. D. 2006) Low High High Low Unclear Unclear 
(Bedaiwy et al. 2007) Low High Low Low Low Low 
(Foda et al. 2012) High Low High Unclear Low Low 
(Vercellini et al. 1993) Low Low Low Low Unclear Low 
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2.3 Data analysis 
 
Due to the nature of this analysis, a random effects model was selected as all 
studies sampled different women under similar circumstances according to the 
rAFS classification system24. Studies were analysed using the Standard Mean 
Difference (SMD) in RStudio (Open source, version v1.2.1335, with R version 
3.0.1) which provides a heterogeneity test, the effect size; as well as confidence 
intervals that displayed test precision. If this range did not overlap ‘0’ a significant 
difference existed, and the further away the confidence in terval range is from ‘0’, 
the more of an effect that is present. The size of the range indicates the precision 
with smaller ranges having more consistently accurate results after analysing all 
studies. The following RStudio ‘library’ packages were used: ‘effsize’, ‘lsr’, ‘meta’, 
‘metafor’, ‘zoom’, and ‘matrix’. Table 2 displays the layout of the CSV (Comma 
delimited) file used in Microsoft Excel for interpretation by RStudio. 
 
Table 2: Data presentation in Excel for RStudio analysis25. Cmean = Control mean, 
CSD = Control Standard Deviation, Cn = Control no. of patients, Emean = 
Experiment mean, ESD = Experiment Standard Deviation, En = Experiment no. of 
patients 
 
Trial Cmean  1 CSD2 Cn3 Emean  ¶ ESD En 































1 Control patients 
2 Control Standard Deviation 






For this analysis 43 studies were selected. From these, 22 were excluded due to 
the incorrect sample type, or because the data type was considered unreliable for 
accurate mean and standard deviation estimates, e.g. log data, and extrapolated 
data from genetics studies. A further 2 studies (73 patients) were excluded 
because they contained data for endometriosis patients, and possessed values of 
‘0’ or ‘not detected’ for control samples. Due to this property, they added no weight 
to the meta-analysis calculation. The remaining 19 studies were considered 
eligible and included 1075 patients. Figure 1 illustrates the PRISMA compliant26 
method for study selection. Table 1 shows the risk of bias assessment for these 
studies. It should be noted that there is selection bias in the majority of studies as 
clinicians intentionally selected those who did and did not have endometriosis or 




Figure 1: PRISMA flow diagram illustrating refinement of studies selected for this 
meta-analysis, adapted from template of Moher et al26. 
From this information, as the heterogeneity test possessed a low p-value (p<0.05) 
and from assessing the nature of the studies without statistical analysis, a random 
effects model was ideal while using the SMD calculation (Figure 2). Also, in Figure 
2, according to the SMD calculation, statistical significance does exist (p=0.0282), 
and furthermore the effect is large (SMD: 2.1753, CI: 0.2598 – 4.0908). By 
consisting of a large confidence interval range close to ‘0’ in  the SMD calculation, 
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the result is also considered imprecise. This idea is explored further in the 
discussion and limitations of these studies. Furthermore, with refinement in future 
studies, the results suggest that TNF-α can be used as one of the early diagnostic 
markers for endometriosis. However, it cannot be the only predicting factor at this 
stage due to the inconsistency and data conflicts in previous studies and those 
seen in this meta-analysis. For further reference, Table 3 provides an overall 
summary of the 21 studies to show means, standard deviations, sample numbers, 
kits used, and whether or not there was a significant difference between the 
patients with and without endometriosis.  
 
Figure 2: RStudio Meta-analysis and heterogeneity test of patient PF TNF-α levels 
(pg/mL) of women with and without endometriosis (SMD = Standardized Mean 
Difference (Hedge’s g), SD = Standard Deviation, CI = Confidence Interval). 
Performed according to RStudio code from Harrer and Ebert25. 
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Table 3: Summary of data for the 21 studies used in the meta-analysis. Any 
estimates performed were done according to formulas of Hozo et al1 and Wan et 
al2. 
Study Control   Endo†   Estimates required?  Kit used p-values 
 Mean SD‡ N§ Mean SD N Yes/No   
(Kalu et al., 2007) 8.00 6.96 23 5.20 1.85 17 Yes - sd estimated ImmuliteTM 0.053 
(Podgaec et al., 
2007) 




using a flow 
cytometer 
0.364 
(Cheong et al., 
2002) 




(Harada et al., 
1997) 




(Bedaiwy et al., 
2002) 





& Ulrich, 2005) 




(Mier-Cab re ra, 
Jimenez-Zamudio, 
Garcia-Latorre, 
Cruz-Orozc o, & 
Hernandez-
Guerrero, 2011) 
262.25 95.57 32 359.75 83.99 32 Yes - Median = mean, 





(Dziunycz et al., 
2009) 
108.01 48.28 20 103.04 48.72 46 No ELISA 0.7743 
(Barcz et al., 2012) 120.8 50.07 24 105.83 52.96 48 Yes - mean and sd 
estimated 








1.68 1.24 17 5.52 2.68 19 No ELISA 0.000001 
(Wickiewicz et al., 
2013) 
2.50 2.00 42 2.00 1.50 36 No Cytometric 
Bead array 
0.1696 
(Pizzo et al., 2002) 0 0 5 127.93
0 





‡ Standard Deviation 
§ Sample size 
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Study Control   Endo†   Estimates required?  Kit used p-values 
 Mean SD‡ N§ Mean SD N Yes/No   
(Rana et al. 1996) 8.1 4.9 8 144.9 71.6 17 No ELISA <0.001 
(Salmeri et al., 
2015) 
 
1.2 0.1 16 130.7 8.9 26 No ELISA <0.001 
 
(Skrzypczak 1995) 2.1 4 12 7 22.6 25 No, values given in 
study assumed as the 
mean. 
ELISA and RIA No signif. 
diff. 
(Wang et al. 2018) 37.06 12.73 30 87.29 14.26 55 No, values given in 
study assumed as the 
mean. 
ELISA <0.05 
(Oepomo, T. D. 
2006) 
 
2.75 2.29 20 144.64 47.12 20 No ELISA 0.00 
(Bedaiwy et al. 
2007) 




(Foda et al. 2012) 12.62 8.5 30 38.03 9.47 37 No ELISA <0.001 
(Vercellini et al. 
1993) 
15.2 26.1 48 21.2 36.4 46 No ELISA No signif. 
diff. 
 
4. Discussion:  
 
This meta-analysis was primarily designed to investigate if TNF-α can be a 
candidate for a future diagnostic test for early stage endometriosis. TNF-α is one 
of the generalized immunological cytokines16; a part of many pleural effusions15, 
and is associated with many other diseases, for example tuberculosis17. Therefore, 
it must be noted that TNF-α can only be used for patients with no other illnesses 
or conditions as these may lead to confounding results. For further endometriosis 
diagnostic accuracy, a combination of TNF-α and other cytokines or hormones 
could be used. Results from this meta-analysis possess a large enough SMD 
value to support an existing effect and, once the limitations described are 
overcome to investigate a potentially narrower confidence interval range, TNF-α 
 
† Endometriosis 
‡ Standard Deviation 
§ Sample size 
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should be considered as a candidate for an accurate diagnostic test. Furthermore, 
although sample size is small (n=19) the total sample size these studies represent 
(n=1075) provide sufficient support for TNF-α to become one of the endometriotic 
diagnostic markers. 
In addition, of the 19 analysed, weighted studies, only one studied TNF-α 
exclusively21. The potential problem of exclusively researching one cytokine is that 
a greater pressure for a successful experiment exists as bias is present for only 
successful research to be published. Due to this successful experiment pressure, 
bias27 can be introduced into meta-analyses as well, altering the confidence 
interval range and SMD. However, when multiple cytokines are measured, this 
suggests less pressure on successful experiments for TNF-α exclusively to be 
considered an accurate endometriosis indicator. This is due to other factors that 
may be significant. This provides studies measuring multiple factors a greater 
credibility as it allows for less publication bias based on successful results of a 
singular cytokine. 
At this time, no other meta-analysis has investigated the value of PF TNF-
α levels in endometriotic against non-endometriotic women. This makes it 
unfeasible to compare results of other papers to this analysis. However, these 
results share similar issues with other reports in the literature; there are 
agreements and conflicts of data and significance of TNF-α levels of PF samples. 
Some studies have found significant differences present21, 28-30, and others 
possess no statistical difference29, 31-33. Once new data sets are developed with 
limitations overcome in multiple research publications; a new meta-analysis must 
be performed to investigate if the significance and confidence interval range is 
valid in a similar manner to Figure 2. Until this second meta-analysis is performed; 









A number of limitations were present in this meta-analysis. Primarily, there is no 
agreed gold standard for measuring endometriotic TNF-α in PF or serum34. This 
may explain some of the range in Figure 2 as different test types have the potential 
to yield different results, e.g. ELISA vs Cytometric bead array. This complicates 
matters when performing meta-analyses as comparisons between different 
studies using different methodology increase the probability of a wider TNF-α 
(pg/ml) range of varying data sets. Also, further variation exists via inter-company 
testing, i.e. ELISA kits developed by different companies. For instance, the same 
sample can be measured with ELISA kits from two different companies and yield 
different results35; although this should not occur with kits that assert similar 
specificity and sensitivity. This can also be seen in a commercial setting as 
validation methods will use ELISA kits from different companies to confirm the 
ideal diagnostic test for their laboratory. These details are recorded for evidence 
and as a reference for the selected test with the reasoning behind it.  
As a Quality Assurance system, possessing a gold standard for a diagnostic 
test is essential. By implementing the gold standard and comparing the same 
measured factor on the selected test (e.g. ELISA for a specific protein) from kits 
of different companies; results can be compared to find the most appropriate 
diagnostic test as well as allow for validations or improvements to current 
methodologies. For example, if a sample of known concentration is performed 
using the current gold standard test and compared to a new test for accuracy; this 
allows for test validation or the potential for new gold standard development. Upon 
searching the literature, few comparisons between different test types for TNF-α 
have been performed, for example those done by Talvitie36 and Leister et al36, 37. 
In addition, only Perdomo-Celis and Narváez22 have suggested that the ELISA is 
the gold standard for TNF-α; however, beyond this, no other test has been 
proposed. This is understandable as TNF-α is currently under analysis to 
investigate if it can be used for endometriosis diagnostics. However, for the 
purposes of a meta-analysis and clinical use, a gold standard for TNF-α (pg/ml) 
would be ideal to clarify its true PF concentration range between studies. 
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In addition to the lack of a gold standard, multiple diagnostic methodologies 
were performed across the analysed studies which could add to the imprecision in 
the results. The following test types were performed using PF TNF-α: ELISA, 
ImmuliteTM, Cytometric bead array, Bioassay using L929 cells, immunoradiometric 
assay (IRMA), and the Multiplex immunoassay. With such inconsistencies, 
inaccuracies, and potential imprecision in the test types used, or a possible 
unknown background effect; any can produce variations in TNF-α. To investigate 
this, validation studies would need to be performed on a number of known TNF-α 
concentrations in samples with all tests compared. This will ascertain which test 
contains the greatest accuracy and precision for a gold standard procedure for 
TNF-α for future use in endometriosis diagnostics.  
Stages of menstrual cycle were also not taken into account in the majority 
of the studies used in this meta-analysis except for one study28. This research 
examined TNF-α levels across different stages in serum and PF with variations 
being present in both sample types28. If menstrual cycle stage is accounted for 
when testing PF TNF-α in multiple studies and a narrower confidence interval 
range is present in the subsequent meta-analysis; this would further explain the 
imprecision within the SMD calculations regarding this meta-analysis, especially 
regarding early diagnosis. By understanding the differences that may exist on PF 
samples during the menstrual cycle, a more accurate range can be found for TNF-
α as well as a comparison that shows the greatest difference between 
endometriotic and non-endometriotic patients. 
Technical error, as well as calibration and maintenance of all equipment 
used for experiments can also decrease precision and accuracy within datasets. 
Although implied, no study mentioned current Quality assurance measures such 
as equipment calibration and maintenance. This introduces further potential error 
as false results can occur with unintentionally inaccurate measurements. Also, 
human error in sample preparation or test performance can influence results. Only 
with appropriate GLP or by separate technicians performing the same test on the 
same sample with currently calibrated equipment can this data be considered 
precise and accurate. However, in practice, using separate technicians on the 
same sample is usually unrealistic and limitations can arise that prevent such ideal 
testing such as cost, time, or the volume of sample obtained from a patient. 
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Furthermore, estimation of means and standard deviations introduce error 
as they are not true values. Although statisticians have developed methods for 
estimation1, 2, original data are preferable. For any paper to be considered for a 
meta-analysis, the following factors should be included: number of samples, 
minimum, maximum, 1st and 3rd quartiles, standard deviation, 95% confidence 
intervals, mean, and median. This allows the most accurate calculations for SMD 
and confidence intervals to be processed in a meta-analysis as well as further use 
in accurate data synthesis methods should these be required. 
 
5. Future research and conclusion: 
 
The next stages of development for early stage endometriosis diagnostic 
research and testing is one that requires careful precision and accuracy. It also 
requires menstrual cycle stages to be recognized regarding such a test, as well as 
the less invasive aspects of sample collection. These procedures are less invasive 
as they involve using a syringe to draw PF from the patient; however, there is more 
inconvenience as the patient will be required to have samples collected on specific 
days of their individual menstrual cycle. In regards to protein analysis, in 
conjunction with TNF-α, other cytokines and hormonal candidates for 
endometriosis must be identified and evaluated for implementation to isolate 
endometriosis diagnosis without laparoscopy. These proteins would be identified 
by meta-analyses using either PF or serum. Furthermore, for the most accurate 
endometriosis diagnosis, secondary conditions that may interfere with results must 
be accounted for. To investigate this, a study on patients with a disease or 
condition causing elevated TNF-α in serum or PF must be performed and 
compared to endometriosis patients. This could be done by implementing a blind 
test comparing endometriotic patients with a secondary condition that also raises 
PF or serum TNF-α against three other groups: patients with endometriosis 
exclusively, patients with the secondary condition measured exclusively, and a 
control group. The resulting information and diagnostics could be used to show 
the accuracy or inaccuracy (e.g. when false-positives arise) of the test when a 
prevailing second condition exists that may interfere with the diagnosis.  
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The main contribution of this meta-analysis is to evaluate the potential of 
PF TNF-α as one of the specific diagnostic markers for early-stage endometriosis. 
Furthermore, once limitations are overcome, and a subsequent meta-analysis is 
performed on TNF-α from research using fixed menstrual cycle stages exclusively; 
a comparison of early endometriotic and non-endometriotic women can be 
performed to confirm if a narrower range does exist for TNF-α to validate its 
application in early stage endometriosis diagnostics. In addition, similar to the 
study of Cheong et al28, analyses must be performed on various selected cytokines 
and hormonal candidates at different stages of the menstrual cycle in PF. These 
must compare menstrual cycle stages of control patients against those who have 
early stage (rAFS 1-2) endometriosis. Upon completion, the data must be used to 
develop reference ranges for the selected proteins of each group. This will reveal 
which candidate combination presents the greatest difference in concentrations 
within PF for development of a more reliable diagnostic test at a specific menstrual 
cycle stage. For this type of testing, a biochemical analyser is proposed as a 
foundation for gold-standard early endometriosis rAFS stage 1-2 testing, because 
of the ease of being able to measure multiple factors in one procedure and 
comparing them to reference ranges. Alternatively, using a multiplex 
immunoassay for cytokine and hormone levels could also be used as these are 
similar to an ELISA but with an added benefit of measuring multiple proteins in one 
procedure. Either of these would require significant validation and inter-laboratory 
comparison panels to confirm, irrespective of laboratory, that this test could 
accurately diagnose early stage endometriosis. This would only be the first 
proposition for future research into this area, and it is plausible that other 
diagnostic tests may be more accurate and precise than the multiplex 
immunoassay or biochemical analyser. However, it appears that a biochemical 
analyser using PF would be an ideal model for early onset endometriosis 
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Chapter 3b: Study Protocol - Serum and Peritoneal fluid implementation for 
less invasive endometriosis diagnostics 
Abstract - Many women are affected by endometriosis, a condition of endometrial 
lesion growth outside the uterus able to initiate chronic pain and infertility. Current 
gold standard diagnosis is via invasive laparoscopy. Attempted less-invasive 
methods use protein analyses including: Interleukins -1β, -6, -8, -10, -12, and -13 
(IL-1β, IL-6, IL-8, IL-10, IL-12, IL-13), tumour necrosis factor-α (TNF-α), Cancer 
antigen-125 (CA-125), vascular endothelial growth factor (VEGF), transforming 
growth factor-β (TGF-β), and Interferon-γ (IFN-γ) in serum and peritoneal fluid 
(PF). However, literature conflicts prevent implementation of these proteins for 
diagnostic procedures. To account for this, this study protocol has been designed. 
Initially, random-effects model meta-analyses on various proteins of both sample 
types will determine significantly different factors (p<0.05). Protein measurement 
considerations will occur at this stage, e.g. biochemical analyser or multiplex 
immunoassay. Subsequently, the selected factors will be measured for (n>=50) 
known control and rAFS (revised American Fertility Society) I-II endometriotic 
patients from both sample types with human ethics approval. Samples will be 
taken at each menstrual cycle stage and confirmed with gold standard 
laparoscopy. Data analysis will determine proteins with significant differences with 
selections based on a common menstrual cycle stage if applicable. A reference 
range for each selected factor and sample type for control and rAFS I-II patients 
will be employed. Test validation will require new patients following a single-blind 
procedure using reference ranges to diagnose patients that have undergone gold 
standard laparoscopy. This protocol aims to develop a less invasive method for 











Endometriosis is a condition affecting 10-15% of women (Jerman & Hey-
Cunningham, 2015) in which uterine cells from the endometrial lining invade the 
body and become painful, parasitic-like lesions that are not eliminated by the 
immune system (Lebovic, Mueller, & Taylor, 2011). There is no consensus about 
the cause of endometriosis; however, retrograde menstruation theory yields the 
most support (Jerman & Hey-Cunningham, 2015; Lebovic et al., 2011). This theory 
states that some cells lost during menstruation can enter blood vessels specifically 
and attach at various sites in the body, e.g. brain, lung tissue, and the pelvic cavity 
(Yang & Huang, 2014). To confirm the diagnosis, the current gold standard 
procedure is an invasive laparoscopy (Nezhat et al., 2010; Tanahatoe & Lambalk, 
2003). In addition, when this procedure is performed, the patient may be in any of 
the revised American Fertility Society (rAFS) stages of endometriosis (Richter, 
Dorn, Rosing, Flaskamp, & Ulrich, 2005). Endometriotic patients typically 
experience dyspareunia, abdominal pain, as well as infertility resulting from lack 
of implantation (Lebovic et al., 2011; Nap, Groothuis, Demir, Evers, & Dunselman, 
2004), and becomes a chronic cause of pain and distress in women.  
 Several studies possess conflicting data sets when using serum and 
peritoneal fluid (PF) for endometriosis diagnostics. For example, in some studies, 
PF TNF-α show significant differences (Richter et al., 2005; Salmeri et al., 2015), 
while others do not (Cheong et al., 2002; Wickiewicz et al., 2013). Similar results 
have been observed in other cytokines, e.g. transforming growth factor-β (TGF-β) 
(Pizzo et al., 2002), IL-6 (Barcz et al., 2012; Liu & Luo, 2000), and IL-8 (Barcz et 
al., 2012). However, it appears that these cytokines may have potential for use in 
diagnostic testing. To confirm this, meta-analyses must be performed to account 
for the conflicts seen in the data sets of multiple studies. Due to the current and 
significant variety of datasets present for serum and PF; it would be further 
recommended to develop a single test using serum and PF to conf irm 








Endometriosis, once established is known to cause changes in concentration of 
various cytokines and hormones (Barcz et al., 2012; Keenan, Chen, Chadwell, 
Torry, & Caudle, 1995). As a result, it is likely that protein candidates exist that can 
be used for endometriosis diagnostics once conflicts in data sets are accounted 
for. The study protocol proposed is to perform multiple PRISMA compliant meta-
analyses (Moher, Liberati, Tetzlaff, Altman, & Group, 2009) on various cytokines 
and hormones from at least 20 studies per protein analysed according to serum or 
PF. This will confirm the candidates for a novel diagnostic quantitative or semi 
quantitative procedure, such as a multiplex immunoassay, or other biochemical 
analyser that can measure protein reference ranges. Should there be less than 20 
studies for some factors, these may still be used for analysis; however, the number 
of studies must be emphasized and accounted for within each meta-analysis. 
Multiple factors must be used for the proposed diagnostic test as this further 
accounts for conflicting studies, resulting in the most feasibly accurate test design.  
Upon completion, the following studies require confirmation of patients by gold 
standard laparoscopy and must account for menstrual cycle stage using serum 
and PF samples. The selected proteins will require measurement through the 
chosen test design on a number of known rAFS I-II stage endometriosis against 
controls to develop the reference ranges for each protein. For validation, another 
number of patients at rAFS 1-2 stage endometriosis against controls must be 
measured and performed in a single-blind test where the individuals performing 
the diagnostic test are unaware of the status of each patient; however, the status 
is known by an outside panel so results can be compared for accuracy of the novel 
procedure. 
 
2.1. Meta-analysis to determine cytokine or hormone candidates. 
 
The meta-analyses data must account for the cytokines and hormones in any 
similar standard unit from individual studies, e.g. pg/mL or be converted to this 
accordingly. Due to the nature of these meta-analyses, the random-effects model 
will be used (Borenstein, Hedges, & Rothstein, 2007). The statistics for these 
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analyses are a Standardized Mean Difference (SMD or Hedge’s g) with the Sidik-
Jonkman method for estimating between study variance as well as the Knapp-
Hartung-Sidik-Jonkman method (Harrer & Ebert). The accumulated studies must 
also possess the average, standard deviation, and number of patients for controls 
compared to experimental groups. If the averages or standard deviations are not 
provided, formulas from (Hozo, Djulbegovic, & Hozo, 2005; Wan, Wang, Liu, & 
Tong, 2014) in Figure 1 can be used or a request sent to the first author of the 
paper to receive such information. An example of the meta-analysis has been 




Figure 1: Formulas used for data synthesis of averages and standard deviations 
(q1 = Lower quartile (25th), q3 = upper quartile (75th)), adapted from Hozo et al., 




Figure 2: RStudio meta-analysis and heterogeneity test of PF TNF-α of women 
with and without endometriosis (SMD = Standardized mean difference (Hedge’s 
g), SD = Standard Deviation, CI = Confidence Interval). A test of heterogeneity is 
provided as part of this test and as p<0.01, a random-effects model was applied. 
Meta-analysis performed according to RStudio code found in (Harrer & Ebert). 
 
In addition, there may be meta-analyses performed prior to this hypothesis, 
therefore they can be used as reference guides for which cytokines to consider, 
e.g. cancer antigen-125 (CA-125) (Ben et al., 1998). For endometriosis 
diagnostics, each selected protein should have p<0.05 from the meta-analysis, 
with at least three cytokines per sample type being recommended for a diagnostic 
procedure. By using this method, the study further acknowledges data conflicts 




2.2. The study to confirm physiological candidates for early-onset 
endometriosis diagnosis. 
 
For the following studies, every procedure must be accompanied by 
complete data sets. This includes the: minimum, maximum, range, 25th and 75th 
quartiles, interquartile range, median, mean, standard error, and standard 
deviation. With the information from the meta-analyses, a semi-quantitative test 
such as the multiplex immunoassay, or ELISA; or a quantitative diagnostic test 
such as a biochemical analyser can be developed to measure reference ranges 
of the three or more proposed proteins from each sample type to yield the greatest 
diagnostic precision. In addition, the same test type will preferably be used (i.e. 
biochemical analyser or multiplex immunoassay) for each protein analysed in the 
selected sample type.  
This study requires at least 50 control patients and 50 experimental patients 
with rAFS stage I-II endometriosis including ethical and written consent with gold 
standard laparoscopy confirmation (Nezhat et al., 2010; Tanahatoe & Lambalk, 
2003). The study must be performed according to menstrual cycle stage for serum 
and PF for analysing the proposed factors from the prior meta-analyses. In this 
instance, knowledge of the status of the patient is required. This will be to develop 
accurate reference ranges or other semi-quantitative conditions that display clear 
differences between rAFS stage I – II endometriosis and control patients in serum 
and PF. Although knowledge of the patient condition does increase the risk of bias 
for this study; it is necessary in order to develop a reference range for diagnostic 
procedures.  
Furthermore, the menstrual cycle stage must be accounted for in this study 
as differences in cytokine levels have been found in the literature (Cheong et al., 
2002) and few studies have accounted for this. Therefore, to develop the most 
accurate diagnostic test, this detail must be included. For example, TNF-α 
measured in stage I-II rAFS endometriosis from a serum sample and a PF sample 
against a control patient where both samples are taken in the proliferative phase 
(see Table 1). This is repeated for other proposed cytokines at each menstrual 
cycle stage. However, as ranges vary for cytokines in each menstrual cycle stage, 
e.g. across days 7-14 of proliferative phase; in diagnostic practice, targeting a 
specific day for a patient would be difficult to implement, and this must also be 
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taken into account. The potential for significant differences at each stage will be 
measured by an ANOVA comparing the factors at each menstrual cycle stage with 
p<0.05 as the criteria for each factor.  
 
Table 1: Example of measurement of a selected protein in serum and PF at 
proliferative phase of menstrual cycle. 
 Serum PF 
Subject Control 
(pg/ml) 




rAFS I – II 
(pg/ml) 
1 X X x X 
N X X x X 
 
Once completed, if all menstrual cycle stages are significantly different for 
a protein in serum and PF, samples can be used from any menstrual cycle stage; 
however, this appears unlikely. Therefore, of the proposed cytokines from this 
study, all those with significant differences at a common menstrual cycle stage 
should be employed for patient and medical practitioner convenience. If th ere are 
significant differences across multiple menstrual cycle stages, the stage with the 
lowest p-value should be utilized. However, if a protein exhibits a significance 
(p<0.05) across multiple menstrual cycle stages in common with others 
possessing a difference at a single common menstrual cycle stage; the protein 
with multiple significant differences across menstrual cycle stages must be used 
at the same stage as those with the single significant difference. The reasoning 
being that in medical practice, this will be a more feasible option. For example, if 
serum IL-6 and IL-8 are significant at the proliferative phase of the menstrual cycle, 
and serum IL-10 is significantly different across all stages (p<0.01) of the 
menstrual cycle, samples should be taken at the proliferative phase to measure 
the levels of IL-6, IL-8, and IL-10. The same protocol should be instituted for PF 
where applicable. Once the study is complete with significant differences and 
menstrual cycle stages accounted for; the collected data can be used to develop 
reference ranges if the biochemical analyser is selected. Alternatively, the 
conditions required for a semi-quantitative procedure can also be established for 
the diagnostic test by using the same datasets. 
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2.3. Diagnostic Validation Procedure 
 
To validate the newly developed procedure, a single-blind test must be 
applied. For this validation, at least 50 new rAFS stage I – II endometriotic patients 
and 50 control patients will be analysed by the new procedure with the associated 
menstrual cycle stage accounted for. All patients must have some form of 
identification and their condition confirmed by gold standard laparoscopy (Nezhat 
et al., 2010; Tanahatoe & Lambalk, 2003). The laparoscopy results will be used 
as the reference to compare to the results of the proposed diagnostic test. The 
group performing the diagnostic test, on the other hand, must have no knowledge 
of the conditions of any patient, but will possess the identification of each patient. 
The procedure must be performed and results developed by the diagnostic group 
as to which patients were considered to be endometriotic or not according to the 
identification of each patient. To analyse this information compared to the gold 
standard, a simple percentage analysis can be performed. Correct diagnostics will 
be recorded and a total will be calculated to confirm diagnostic accuracy. For 
example, if 48 of 50 controls were diagnosed correctly and 49 of 50 endometriotic 
patients were diagnosed correctly, therefore 97% of the new diagnostic procedure 
was correct. A minimum of 95% accuracy is recommended for this procedure. 
For a standardised diagnostic procedure, this screening test would need to 
be optional and recommended at 6-month, annual, or patient preference intervals. 
A confirmatory gold standard laparoscopy would only be required when results are 
positive from the new procedure and the patient or medical practitioner possess a 











2.4. Alternatives and Troubleshooting 
 
It is plausible that there will be no common menstrual cycle stages with two or 
more cytokines possessing a statistically significant difference in serum or PF 
(p<0.05). Should this occur, testing protocol would require measuring the 
significantly different factors from the two sample types at the closest intervals of 
the menstrual cycle for patient convenience. For example, if IL-6 is only significant 
at the proliferative phase, and IL-8 at the secretory phase, then a sample must be 
taken in between or at both of these phases. The same validation procedure 
(Method section 3) outlined above will be applied. If successful, when this method 
of two or more cytokines at separate menstrual cycle stages are used for regular 
diagnostic testing, a patient would have serum and PF samples taken at the two 
separate stages with the new diagnostic test performed. 
To account for potential false-positives and false negatives, the patient must 
have their current health status taken into account, e.g. if a pre-existing or ongoing 
condition exists, the patient is taking any medication, or is ill at the time of testing. 
These three factors may cause elevation or depression of protein concentrations 
that can cause a false-result to occur. Furthermore, for the most accurate test, the 
specificity and sensitivity must be at least 95%. Additionally, the menstrual cycle 
stage as well as at least three proteins must be used from serum and PF for the 
diagnostic procedure in the initial validation stage. The reasoning for this being 
that due to the conflicts in the literature, using multiple proteins of different sample 
types will yield the most precise result and narrow the possibility of false-results. 
Furthermore, should fewer proteins be used, there is a greater potential for false-
results to arise. Also, by taking these described factors into account, this will likely 
prevent unnecessary treatments should a false-positive occur. If there is still any 
uncertainty, a laparoscopy can still be performed if required. 
If there are no significant differences in any cytokine measured irrespective of 
sample type at the meta-analysis or diagnostic testing level, or not enough studies 
are present regarding certain factors for testing, it is important for this information 
to be published with these critical evaluation points. Primarily; the proteins used 
may no longer be required for consideration in further studies for potential 
endometriosis diagnostic candidates. However, should the same or different 
proteins be considered, all research must include the original information: sample 
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size, mean, standard deviation, minimum, maximum, range, 25 th and 75th 
quartiles, interquartile range, median, and standard error. This is so meta-analyses 
can possess the most accurate results regarding measurements of any potential 
protein for consideration in the diagnostic procedure. Secondarily, more research 
must be performed on factors with less studies or those not considered in the 
conducted meta-analyses along with examples. Subsequently, all following 
studies must be performed according to menstrual cycle stage for the most 
accurate meta-analyses to be performed to confirm significant or non-significant 
factors. Following this, the methodology described above should be re-evaluated 




Primarily, no physiological based test has been designed for endometriosis, nor 
has any specific test been proposed for serum or PF with multiple factors. This is 
due to the numerous literature data conflicts, suggesting that such methods are 
unlikely to be accurately performed. In addition, due to these conflicts, a single 
factor from two sample types is not recommended for an accurate endometriosis 
diagnosis. At least three factors from two sample types are required for a 
successful, precise test design to justify the result with respect to conflicts in the 
literature with a significant difference for each protein found by meta-analysis. The 
design for a protein-based endometriosis test is ambitious due to: the amount of 
data required, the time required for analysis, the intensity of the studies to follow 
as described above to confirm candidates; and the design of the test for a single 
or multiple menstrual cycle stage analysis.  
Furthermore, test validation would be time-consuming depending on the 
selected diagnostic test used to determine true endometriosis; as well as 
comparing this to known experiment and control patients. Other ailments, 
illnesses, or injuries could also be a potential confounding factor as cytokine and 
hormone level changes that are shared with endometriosis can occur. For 
example, elevated serum concentrations of TGF-β, and TNFα in endometrial 
cancer (Chopra, Ding, & Hannigan, 1997), which are also found in endometriosis 
(Bedaiwy et al., 2002; Pizzo et al., 2002). In addition, when analysed by serum, 
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some cytokine levels, e.g. IL-6 have differing levels of elevation between 
endometriosis and endometrial carcinoma (Slater, Cooper, & Murphy, 2006), and 
this must also be considered regarding interpretations when developing a 
diagnostic test. Therefore, a p<0.01 – p<0.05 between control and experiment 
patients for protein concentrations are recommended for the most accurate 
diagnosis with no adverse conditions that could affect results. Should such 
patients with pre-existing conditions appear, these factors must be taken into 
consideration when interpreting physiological results and may still require 
laparoscopy for confirmation.  
By implementing multiple meta-analyses, the proposed study aims to 
alleviate the issue of invasive endometriosis diagnostic procedures and conflicts 
of data by promoting a comparison of multiple factors in serum and PF. These 
results can provide candidates for use in diagnostic procedures. Meta-analyses 
are recommended as they investigate for consistency between studies, being able 
to account for conflicts between datasets and varying sample sizes. As a result of 
this, they provide the most precise estimates of true effects (Haidich, 2010) and 
thus reveal the ideal proteins.  
Furthermore, accuracy increases when menstrual cycle stage is recorded 
as this can potentially isolate candidates with the greatest observed differences in 
concentration. One study has shown that such differences exist at various cycle 
stages (Cheong et al., 2002), and therefore, for the most precise test design, these 
stages must be considered. By using a follow-up study to find and compare rAFS 
I – II patients to controls, reference ranges can be developed according to 
menstrual cycle phase that can be used to find which proteins possess the most 
significance as described above. However, if significant differences occur across 
all menstrual cycle phases (p<0.05), it facilitates diagnosis through only one test 
being performed at any phase, rather than targeting a specific day of the menstrual 
cycle in a patient.  
If the reference ranges are developed, compared, and show significant 
concentration differences (p<0.05), the validation procedure can be performed as 
described above in the single-blind procedure. If successful, the designed test can 
proceed for diagnostic application. Table 2 provides an example using serum for 
test result interpretation. By possessing this earlier detection method for 
endometriosis, more conservative treatments can be used. The result being the 
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prevention of further chronic and increasing pain associated with progressive 
endometriosis. If testing was required at multiple menstrual cycle stages, there 
may be difficulties with a patient returning at the correct menstrual cycle stage for 
confirmatory diagnosis, however this method is still plausible.  
 

















Positive Positive Positive Positive Positive No, only required 
at doctor discretion 
or patient request. 
Positive Negative Positive Positive 
or 
negative 




Negative Negative Positive Positive 
or 
negative 




Negative Negative Negative Negative Negative No 
 
This study protocol has been developed with the intention of designing a 
gold standard of testing at the earliest stage of endometriosis detection. By 
designing a simple, economic test as a routine procedure, patient request, or 
doctor recommendation for early diagnosis, it allows application of the earliest 
possible treatment. It is different from current methodologies as patients can 
request for a physical check using the rAFS system for endometriosis if desired, 
but this will be more invasive when compared to a physiological measure. 
Currently, unless a patient undergoes regular uterine physical exams, 
endometriosis can only be diagnosed after a patient is in pain and has visited a 
specialist medical practitioner. In addition, patients may report pain and discomfort 
74 
 
at any stage of endometriosis; however, this protein -based test can yield a more 
accurate early-stage detection method. Additionally, it must be noted, that in some 
instances, endometriosis may be asymptomatic (Hickey, Ballard, & Farquhar, 
2014), further showing that a minimum of a number of a routine annual or patient 
preference check-up could be applied. 
There is also potential for a business profit with the design of such a test, 
as no cytokine or hormonal test has been designed and used for endometriosis 
diagnosis at the earliest possible stage, on a routine basis, and in a protein -based 
manner. Furthermore, this design may address another area of concern regarding 
pricing compared to current methodologies. Depending on the type of test 
requested, e.g. physical exam or hormonal drug therapies (Kennedy et al., 2005) 
and where it is performed, prices will vary (Simoens et al., 2012; Simoens, 
Hummelshoj, & D'Hooghe, 2007). However, current methods appear to be similar 
or more expensive in cost than a hormonal or cytokine-based test.  
For the proposed method to be put into practice, there is a high risk-benefit 
association; where the benefit has been described above. However, the risk of 
such a large study by meta-analyses and validation could result in not having any 
viable hormone or cytokine for endometriosis testing by physiological means. The 
scenario of no significantly different factors in two sample types by two menstrual 
cycle stages appears unlikely considering the number of cytokines and hormones 
undergoing analyses. If there is no difference in any cytokine or hormone, this 
information is important for publication. This is because it will assist other 
researchers to investigate different methods for less-invasive endometriosis 
diagnostics not yet considered, rather than repeating errors resulting in substantial 
loss of time and finances. The additional benefit, should this design succeed, 
would be a standard test for women globally that allows for earlier endometriosis 










The result of the proposed study protocol suggests that factors likely exist for a 
less-invasive physiological endometriosis diagnostic test. The observations from 
existing research by meta-analysis, for example serum cancer antigen 125 (CA-
125) (Hirsch, Duffy, Davis, Plana, & Khan, 2016), also present potential for an 
early onset-endometriosis diagnostic procedure. Even though conflicts in the 
literature exist, multiple meta-analyses can account for these to provide the most 
accurate and precise final result for each analysed cytokine. Furthermore, to 
provide greater accuracy, the proposed meta analyses must be performed on 
serum and PF samples simultaneously. By using these two sample types, 
preferably with an identical diagnostic test such as the multiplex immunoassay or 
biochemical analyser comparing cytokines to standardized reference ranges; this 
should provide the most plausible method to confirm early-onset endometriosis. It 
is also intended to act as a new gold standard for future tests to be compared 
against.  
Moreover, further research into each proposed diagnostic factor at each 
menstrual cycle stage is required to confirm if major differences between rAFS I – 
II stage endometriosis and control patients exist. This will also confirm if the 
proposed diagnostic test will be more accurate at certain menstrual cycle stages. 
In addition, when testing, the condition of the patient must be accounted for so that 
no confounding factors exist that could unintentionally produce false positives or 
negatives. The proposed method aims to discover which factors are the most 
significant for diagnostic analysis with the resulting medical laboratory test being 
less invasive than current methodologies. This diagnostic procedure is also 
designed to be an economical, routine, easy-to-perform screening test with a 
confirmatory laparoscopy only being required at the request of the patient or by 
recommendation of the medical practitioner. Should this method be successful, it 
will further allow for earlier endometriosis diagnoses and treatment; a result 
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Chapter 4: Conclusion 
4.1 Overview 
Due to the prevalence of endometriosis, investigating its mechanisms of 
action, as well as the ideal method for the earliest possible diagnosis and treatment 
is imperative. This thesis has covered endometrial development and the four 
current endometriosis theories. Following this, a PRISMA compliant meta-analysis 
was performed to research if PF TNF-α could become a candidate for an early 
stage (equivalent to rAFS I-II) endometriosis diagnostic procedure. As the results 
had p<0.05 for this analysis, it is reasonable to suggest that PF TNF-a can be used 
for future diagnostic procedures with some refinement. Consequently, a study 
protocol has been developed using the same meta-analysis methodology on 
serum and PF of multiple proteins. Should significant differences exist between 
endometriotic and control patients of the newly chosen proteins; they could be 
refined to develop reference ranges according to menstrual cycle stage between 
known endometriotic and control patients. These reference ranges could be 
developed using a semi-quantitative test, e.g. ELISA, or a quantitative test, e.g. 
biochemical analyser. Once data sets were compared, at least three proteins with 
significant differences (p<0.05) at a common menstrual cycle stage in serum and 
PF would be selected for the final validation procedure. This procedure would 
include a new set of patients with rAFS I-II stage endometriosis and controls; using 
a single-blind procedure with all patients being given unique identifications and 
diagnosed using gold standard laparoscopy. The validation process would use the 
newly developed reference ranges for PF and serum to diagnose the patients 
according to their identifications. The diagnoses between the gold standard and 
the new procedure would be compared to determine the accuracy, with >95% 









4.2 Strengths and limitations of this study 
 
4.2.1 Strengths 
 The strength in this thesis lies within the analytical process. By reviewing 
endometriosis and endometrial development, proteins could be utilized within 
diagnostics laboratories. Furthermore, by using a meta-analysis, literature 
conflicts are accounted for with weights given according to sample sizes in each 
study. This allows for greater precision and accuracy to determine if a specific 
protein has diagnostic potential. In addition, performing more meta-analyses on 
other proteins of different sample types is straightforward to repeat. This causes 
protein selection for diagnostics to become a much simpler process within a study 
protocol. Also, the study protocol is logical and could determine accurate reference 
ranges for women at each menstrual cycle phase for comparisons between 
endometriotic and control patients. 
 
4.2.2 Limitations 
 Some limitations must also be accounted for in this thesis. Primarily, the full 
process of endometriosis is not understood as evidenced in the literature review. 
Not all biochemical pathways are known and there is no consensus on the 
development and process of ectopic lesion growth with the associated symptoms. 
Additionally, the meta-analysis possessed numerous limitations as discussed 
such as: no gold standard present for TNF-α (Freeman et al., 2016), the number 
of different tests used for measuring TNF-α, and the menstrual cycle stage not 
being accounted for in each study. More studies may also have been present that 
could have been included; however, many could not be used due to limited access 
to some research articles, as well as articles outside the scope of criteria for the 
meta-analysis. Also, in some instances, data estimation formulas were required 
(Hozo, Djulbegovic, & Hozo, 2005; Wan, Wang, Liu, & Tong, 2014) where original 
data could not be accessed, which could further increase the error and confidence 
interval range seen in the meta-analysis. The study protocol is limited in terms of 
the time and finance required for the reference range, validation procedure, and. 
the potential for no common menstrual cycle stage for proteins with significantly 




4.3 Implications and final remarks 
 The implications of this thesis provide evidence that meta-analyses can be 
performed to study if the data from multiple studies is consistent, with PF TNF-α 
as a potential diagnostic candidate. If the data is consistent with proteins of 
significant differences, these candidates could proceed to the next phase of 
diagnostic validation. Once proteins are found, reference ranges can be developed 
and analysed to narrow which candidates from serum and PF possess the most 
support for the diagnostic procedure. Upon completion, a single-blind validation 
will be used to compare gold standard laparoscopy to the new diagnostic process 
for accuracy confirmation. If successful, this new test can be put into the next 
phase for human trials and be implemented on a patient preference; three-month, 
six-month, or annual basis as a routine screening procedure for the earliest 
plausible endometriosis diagnosis. This will result in earlier treatments and less 
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